WO2019060742A1 - AGENTS FOR DEGRADING PROTEINS AND USES THEREOF - Google Patents

AGENTS FOR DEGRADING PROTEINS AND USES THEREOF Download PDF

Info

Publication number
WO2019060742A1
WO2019060742A1 PCT/US2018/052242 US2018052242W WO2019060742A1 WO 2019060742 A1 WO2019060742 A1 WO 2019060742A1 US 2018052242 W US2018052242 W US 2018052242W WO 2019060742 A1 WO2019060742 A1 WO 2019060742A1
Authority
WO
WIPO (PCT)
Prior art keywords
agent
nitrogen
sulfur
oxygen
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2018/052242
Other languages
English (en)
French (fr)
Inventor
Nello Mainolfi
Nan JI
Yi Zhang
Matthew M. Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymera Therapeutics Inc
Original Assignee
Kymera Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to IL295603A priority Critical patent/IL295603B2/en
Priority to EP18857581.5A priority patent/EP3684365A4/en
Priority to IL273432A priority patent/IL273432B/en
Priority to IL307995A priority patent/IL307995A/en
Priority to EP25195747.8A priority patent/EP4624467A3/en
Priority to AU2018338314A priority patent/AU2018338314B2/en
Priority to US16/649,732 priority patent/US11623932B2/en
Priority to CA3076613A priority patent/CA3076613A1/en
Priority to MX2020003190A priority patent/MX2020003190A/es
Priority to JP2020538753A priority patent/JP7366031B2/ja
Application filed by Kymera Therapeutics Inc filed Critical Kymera Therapeutics Inc
Priority to IL322809A priority patent/IL322809A/en
Publication of WO2019060742A1 publication Critical patent/WO2019060742A1/en
Anticipated expiration legal-status Critical
Priority to US17/837,449 priority patent/US20230115184A1/en
Priority to JP2023175302A priority patent/JP7818560B2/ja
Priority to AU2025201796A priority patent/AU2025201796A1/en
Priority to US19/304,052 priority patent/US20260085075A1/en
Priority to JP2025136973A priority patent/JP2025170324A/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/14—Ortho-condensed systems

Definitions

  • the present invention relates to compounds and methods useful for the modulation of targeted ubiquitination, especially with respect to a variety of polypeptides and other proteins, which are degraded and/or otherwise inhibited by compounds according to the present invention.
  • the invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
  • UPP Ubiquitin-Proteasome Pathway
  • E3 ubiquitin ligases comprise over 500 different proteins and are categorized into multiple classes defined by the structural element of their E3 functional activity.
  • Cereblon interacts with damaged DNA binding protein 1 and forms an E3 ubiquitin ligase complex with Cullin 4 where it functions as a substrate receptor in which the proteins recognized by CRBN might be ubiquitinated and degraded by proteasomes.
  • CRBN Proteasome-mediated degradation of unneeded or damaged proteins plays a very important role in maintaining regular function of a cell, such as cell survival, proliferation and growth.
  • a new role for CRBN has been identified; i.e., the binding of immunomodulatory drugs (EVIiDs), e.g. thalidomide, to CRBN has now been associated with teratogenicity and also the cytotoxicity of EVIiDs, including lenalidomide, which are widely used to treat multiple myeloma patients.
  • EVIiDs immunomodulatory drugs
  • thalidomide e.g. thalidomide
  • CRBN is likely a key player in the binding, ubiquitination and degradation of factors involved in maintaining function of myeloma cells.
  • UPP plays a key role in the degradation of short-lived and regulatory proteins important in a variety of basic cellular processes, including regulation of the cell cycle, modulation of cell surface receptors and ion channels, and antigen presentation.
  • the pathway has been implicated in several forms of malignancy, in the pathogenesis of several genetic diseases (including cystic fibrosis, Angelman's syndrome, and Liddle syndrome), in immune surveillance/viral pathogenesis, and in the pathology of muscle wasting.
  • the UPP is used to induce selective protein degradation, including use of fusion proteins to artificially ubiquitinate target proteins and synthetic small-molecule probes to induce proteasome-dependent degradation.
  • Bifunctional compounds composed of a target protein- binding ligand and an E3 ubiquitin ligase ligand, induced proteasome-mediated degradation of selected proteins via their recruitment to E3 ubiquitin ligase and subsequent ubiquitination. These drug-like molecules offer the possibility of temporal control over protein expression.
  • Such compounds are capable of inducing the inactivation of a protein of interest upon addition to cells or administration to an animal or human, and could be useful as biochemical reagents and lead to a new paradigm for the treatment of diseases by removing pathogenic or oncogenic proteins (Crews C, Chemistry & Biology, 2010, 17(6):551-555; Schnnekloth JS Jr., Chembiochem, 2005, 6(l):40-46).
  • the present application relates novel bifunctional compounds, which function to recruit targeted proteins to E3 Ubiquitin Ligase for degradation, and methods of preparation and uses thereof.
  • the present disclosure provides bifunctional compounds, which find utility as modulators of targeted ubiquitination of a variety of polypeptides and other proteins, which are then degraded and/or otherwise inhibited by the bifunctional compounds as described herein.
  • An advantage of the compounds provided herein is that a broad range of pharmacological activities is possible, consistent with the degradation/inhibition of targeted polypeptides from virtually any protein class or family.
  • the description provides methods of using an effective amount of the compounds as described herein for the treatment or amelioration of a disease condition, such as cancer, e.g., multiple myeloma.
  • the present application further relates to targeted degradation of proteins through the use of bifunctional molecules, including bifunctional molecules that link a cereblon-binding moiety to a ligand that binds the targeted protein.
  • the present application also relates to a bifunctional compound having the following structure:
  • TBM is a target binding moiety capable of binding to the targeted protein(s);
  • L is a bivalent moiety that connects TBM to UBM
  • UBM is a ubiquitin binding moiety capable of binding to a ubiquitin ligase such as an E3 Ubiquitin Ligase (e.g., cereblon).
  • a ubiquitin ligase such as an E3 Ubiquitin Ligase (e.g., cereblon).
  • Compounds provided by this invention are also useful for the study of CRBN and targeted proteins in biological and pathological phenomena; the study of CRBN and targeted proteins occurring in bodily tissues; and the comparative evaluation of new CRBN or targeted protein ligands or other regulators of CRBN or targeted proteins in vitro or in vivo.
  • binding As defined herein, the terms “binder,” “modulator,” and “ligand” are used interchangeably and describe a compound that binds to, modulates or is a ligand for CRBN or a targeted protein.
  • the present invention provides a compound of formula I:
  • X 1 a bivalent moiety selected from a covalent bond, -CH 2 - -C(O)-, -C(S)-,
  • R is hydrogen, deuterium, halogen, -CN, OR, SR, -S(0)R, -S(0) 2 R, -NR 2 , or an optionally substituted Ci-4 aliphatic; each R 2 is independently hydrogen, -R 6 , halogen, -CN, -NO2, -OR, -SR, - R 2 , -S(0) 2 R, -S(0) 2 R 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • Ring B is a fused ring selected from 6-membered aryl containing 0-2 nitrogen atoms, 5 to 7- membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5- membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • R 3 is selected from hydrogen, halogen, -OR, -N(R) 2 , or -SR;
  • each R 4 is independently hydrogen, -R 6 , halogen, -CN, -NO2, -OR, -SR, - R 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • R 5 is hydrogen, C1-4 aliphatic, or -CN
  • each R 6 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)-, -S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) 2 -, -N(R)S(0) 2 -, -S(0) 2 N(R)-, -N(R)C(0)-,
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen
  • TBM is a target binding moiety
  • n 0, 1, 2, 3 or 4;
  • each of n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of formula I':
  • X 1 is a bivalent moiety selected from a covalent bond, -CH 2 - -C(O)-, -C(S)-, or
  • R 1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, -S(0) 2 R, -NR 2 , or an optionally substituted Ci-4 aliphatic;
  • each R 2 is independently hydrogen, -R 6 , halogen, -CN, -N0 2 , -OR, -SR, -NR 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0)NR 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • Ring A is a bi- or tricy wherein Ring B is other than imidazo or benzo, ein Ring B is other than benzo, wherein Ring B is other than benz
  • Ring B is other than benzo
  • Ring B is a fused ring selected from 6-membered aryl containing 0-2 nitrogen atoms, 5 to 7- membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5- membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • R 3 is selected from hydrogen, halogen, -OR, -N(R) 2 , or -SR;
  • each R 4 is independently hydrogen, -R 6 , halogen, -CN, -N0 2 , -OR, -SR, - R 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • R 5 is hydrogen, Ci-4 aliphatic, or -CN;
  • each R 6 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)-, - S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) 2 -, -N(R)S(0) 2 -, -S(0) 2 N(R)-, -N(R)C(0)-, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1 -2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen,
  • TBM is a target binding moiety
  • n 0, 1, 2, 3 or 4;
  • each of n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of formula I":
  • X 1 is a bivalent moiet selected from a covalent bond, -C(R) 2 - -C(O)-, -C(S)-, -P(0)(OR)-, -
  • X 2 is a carbon atom or silicon atom
  • X 3 is a bivalent moiety selected from -C(R) 2 - -N(R)-, -CF 2 - -CHF-, -S-, or -0-;
  • X 4 is a bivalent moiety selected from a covalent bond or -C(R) 2 -;
  • — is a single bond or double bond
  • R 1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, -S(0) 2 R, - R 2 , -P(0)(OR) 2 , -P(0)( R 2 )OR, -P(0)( R 2 ) 2 , -Si(OH) 2 R, -Si(OH)(R) 2 , -Si(R) 3 , an optionally substituted C 1-4 aliphatic, or:
  • R 1 and X 1 or X 4 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, carbocyclic ring or heterocyclic ring having 1-3 heteroatoms, independently selected from nitrogen, oxygen, or sulfur; each R 2 is independently hydrogen, deuterium, -R 6 , halogen, -CN, -N0 2 , -OR, -SR, -NR 2 , -Si(OH) 2 R, -Si(OH)(R) 2 , -Si(R) 3 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0)NR 2 , -C(0)N(R)OR, -OC(0)R, -OC(0)NR 2 , -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N
  • Ring B is a fused ring selected from 6-membered aryl containing 0-3 nitrogen atoms, 5 to 7- membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5 -membered heteroaryl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur;
  • R 3 is selected from hydrogen, deuterium, halogen, -CN, -N0 2 , -OR, - R 2 , -SR, -S(0) 2 R, -S(0) 2 R 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0) R(OR), -OC(0)R, -OC(0) R 2 , -OP(0)(OR) 2 , -OP(0)( R 2 ) 2 , -OP(0)( R 2 ) 2 , -OP(0)( R 2 ) 2 , -OP(0)(OR) R 2 , -N(R)C(0)R, -N(R)C(0)OR, -N(R)C(0) R 2 , -N(R)S(0) 2 R, -N(R)S(0) 2 NR 2 , -N(R)P(0)(OR) 2 , -N(R)P(0)(OR) R 2 , -P(0)(OR)
  • each R 4 is independently hydrogen, deuterium, -R 6 , halogen, -S(0) 2 R, -S(0) 2 R 2; -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -P(0)(OR) 2 , -P(0)( R 2 )OR, or -P(0)( R 2 ) 2 ;
  • R 5 is hydrogen, deuterium, an optionally substituted C1-4 aliphatic, or -CN;
  • each R 6 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur;
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)- , -Si(R) 2 - -Si(OH)(R)-, -Si(OH) 2 - -P(0)(OR)-, -P(0)(R)-, -P(0)( R 2 )-, -S-, - OC(O)-, -C(0)0- -C(O)-, -S(O)-, -S(0) 2 - -N(R)S(0) 2 - -S(0) 2 N(R)-,
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 3-8 membered saturated or partially unsaturated carbocyclylenyl, a 6-11 membered saturated or partially unsaturated spiro carbocyclylenyl, a 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-10 membered saturated or partially unsaturated heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur, a 6-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur, a 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated heterocyclylenyl having 1-4 heteroatoms independently
  • TBM is a target binding moiety
  • n 0, 1, 2, 3 or 4;
  • each of n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, deuterium, or an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • Ring B where a point of attachment of is depicted on Ring B, it is intended, and one of ordinary skill in the art would appreciate, that the point of attachment of may be on Ring A and may also be at any available carbon or nitrogen atom on
  • Ring A including the ring to which Ring B is fused. Where is attached to a nitrogen atom bound to R 4 or R 5 R 4 or R 5 is absent and takes the lace of the
  • Ring A when is attached to Ring B, Ring A is when is attached to Ring A, Ring A is when d to a nitrogen atom bound to R 4 , Ring A is
  • Ring A is
  • the present invention provides a compound of Formula II-A:
  • a bivalent moiety selected from a covalent bond, -CH 2 - -C(O)-, -C(S)-,
  • each R 2 is independently hydrogen, -R 4 , halogen, -CN, -NO2, -OR, -SR, - R 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; each R 3 is independently hydrogen, -R 4 , halogen, -CN, -NO2, -OR, -SR, -NR 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0)NR 2 , -C(0)N(R)OR, -OC(0)R, -OC(0)NR 2 , -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0)NR 2 , or -N(R)S(0) 2 R;
  • each R 4 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • R 5 is hydrogen, C 1-4 aliphatic, or -CN;
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)-, - S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) 2 -, -N( -, -S(0) 2 N(R -, -N(R)C(0)-, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1 -2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroaryl enyl having 1-4 heteroatoms independently selected from nitrogen
  • TBM is a target binding moiety
  • n 0, 1, or 2;
  • each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of formula II'-A:
  • X 1 a bivalent moiety selected from a covalent bond, -CH 2 - -C(O)-, -C(S)-,
  • R is hydrogen, deuterium, halogen, -CN, OR, SR, -S(0)R, -S(0) 2 R, -NR 2 , or an optionally substituted Ci-4 aliphatic; Ring - or bicyclic ring selected from
  • each R 2 is independently hydrogen, -R 4 , halogen, -CN, -NO2, -OR, -SR, - R 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; each R 3 is independently hydrogen, -R 4 , halogen, -CN, -NO2, -OR, -SR, -NR 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0)NR 2 , -C(0)N(R)OR, -OC(0)R, -OC(0)NR 2 , -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0)NR 2 , or -N(R)S(0) 2 R;
  • each R 4 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • R 5 is hydrogen, C 1-4 aliphatic, or -CN;
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)-, - S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) 2 -, -N( -, -S(0) 2 N(R -, -N(R)C(0)-, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1 -2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroaryl enyl having 1-4 heteroatoms independently selected from nitrogen
  • TBM is a target binding moiety
  • n 0, 1, or 2;
  • each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of Formula II"-A:
  • X 1 is ivalent moiety selected from a covalent bond, -C(R) 2 - -C(O)-, -C(S)-, -P(0)(OR)-, -
  • X 2 is a carbon atom or silicon atom
  • X 3 is a bivalent moiety selected from -C(R) 2 - -N(R)-, -CF 2 - -CHF-, -S-, or -0-;
  • X 4 is a bivalent moiety selected from a covalent bond or -C(R) 2 -;
  • — is a single bond or double bond
  • R 1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, -S(0) 2 R, - R 2 , -P(0)(OR) 2 , -P(0)( R 2 )OR, -P(0)( R 2 ) 2 , -Si(OH) 2 R, -Si(OH)(R) 2 , -Si(R) 3 , an optionally substituted Ci-4 aliphatic, or: R 1 and X 1 or X 4 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, carbocyclic ring or heterocyclic ring having 1-3 heteroatoms, independently selected from nitrogen, oxygen, or sulfur;
  • each R 2 is independently hydrogen, deuterium, -R 6 , halogen, -CN, -N0 2 , -OR, -SR, - R 2 , -Si(OH) 2 R, -Si(OH)(R) 2 , -Si(R) 3 , -S(0) 2 R, -S(0) 2 R 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , -N(R)S(0) 2 R, -N(R)S(0) 2 R 2 , -P(0)(OR) 2 , -P(0)( R 2 )OR, or -P(0)( R 2 ) 2 ;
  • Ring B is selected from a 6-membered aryl containing 0-3 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur; each R 3 is selected from hydrogen, deuterium, halogen, -CN, -NO2, -OR, - R 2 , -SR, -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0) R(OR), -OC(0)R, -OC(0) R 2 , -OP(0)(OR) 2 , -OP(0)( R 2 ) 2 , -OP(0)( R 2 ) 2 , -OP(0)( R 2 ) 2 , -OP(0)(OR) R 2 , -N(R)C(0)R, -N(R)C(0)OR, -N(R)C(0) R 2 , -N(R)S
  • each R 4 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • R 5 is hydrogen, deuterium, an optionally substituted C1-4 aliphatic, or -CN;
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)- , -Si(R) 2 - -Si(OH)(R)-, -Si(OH) 2 - -P(0)(OR)-, -P(0)(R)-, -P(0)(NR 2 )-, -S-, - OC(O)-, -C(0)0- -C(O)-, -S(O)-, -S(0) 2 - -N(R) - -S(0) 2 N(R)- -N(R)C(0)-, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 3-8 membered saturated or partially unsaturated carbocyclylenyl, a 6-1 1 membered saturated or partially unsaturated spiro carbocyclylenyl, a 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-10 membered saturated or partially unsaturated heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur, a 6-1 1 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur, a 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated heterocyclylenyl having 1-4 heteroatom
  • TBM is a target binding moiety
  • n 0, 1, or 2;
  • n 0, 1, 2, 3, or 4;
  • p is 0 or 1, wherein when p is 0, the bond connecting Ring A and Ring B is connected to
  • each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of Formula II-B:
  • a bivalent moiety selected from a covalent bond, -CH 2 - -C(O)-, -C(S)-,
  • Ring A is a mono- or bicyclic ring selected from
  • each R 2 is independently hydrogen, -R 4 , halogen, -CN, -N0 2 , -OR, -SR, -NR 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0)NR 2 , -C(0)N(R)OR, -OC(0)R, -OC(0)NR 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0)NR 2 , or -N(R)S(0) 2 R;
  • Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; each R 3 is independently hydrogen, -R 4 , halogen, -CN, -NO2, -OR, -SR, - R 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • each R 4 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • R 5 is hydrogen, C1-4 aliphatic, or -CN
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)-, - S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) 2 -, -N( -, -S(0) 2 N(R -, -N(R)C(0)-, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroaryl enyl having 1-4 heteroatoms independently selected from nitrogen,
  • TBM is a target binding moiety
  • n 0, 1, or 2;
  • n 0, 1, 2, 3, or 4;
  • p is 0 or 1;
  • each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of formula II'-B:
  • Ci-4 aliphatic is hydrogen, deuterium, halogen, -CN, -C OR, SR, -S(0)R, -S(0) 2 R, -NR 2 , or an optionally substituted Ci-4 aliphatic; Ring
  • each R 2 is independently hydrogen, -R 4 , halogen, -CN, -NO2, -OR, -SR, - R 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; each R 3 is independently hydrogen, -R 4 , halogen, -CN, -NO2, -OR, -SR, -NR 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0)NR 2 , -C(0)N(R)OR, -OC(0)R, -OC(0)NR 2 , -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0)NR 2 , or -N(R)S(0) 2 R;
  • each R 4 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • R 5 is hydrogen, C1-4 aliphatic, or -CN;
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)-, - S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) 2 -, -N( -, -S(0) 2 N(R -, -N(R)C(0)-, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen
  • TBM is a target binding moiety
  • n 0, 1, or 2;
  • n 0, 1, 2, 3, or 4;
  • p is 0 or 1;
  • each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of Formula II"-B:
  • X 1 is ivalent moiety selected from a covalent bond, -C(R) 2 - -C(O)-, -C(S)-, -P(0)(OR)-, -
  • X 2 is a carbon atom or silicon atom
  • X 3 is a bivalent moiety selected from -C(R) 2 - -N(R)-, -CF 2 - -CHF-, -S-, or -0-;
  • X 4 is a bivalent moiety selected from a covalent bond or -C(R) 2 -;
  • — is a single bond or double bond
  • R 1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, -S(0) 2 R, - R 2 , -P(0)(OR) 2 , -P(0)( R 2 )OR, -P(0)( R 2 ) 2 , -Si(OH) 2 R, -Si(OH)(R) 2 , -Si(R) 3 , an optionally substituted Ci-4 aliphatic, or:
  • R 1 and X 1 or X 4 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, carbocyclic ring or heterocyclic ring having 1-3 heteroatoms, independently selected from nitrogen, oxygen, or sulfur;
  • each R 2 is independently hydrogen, deuterium, -R 6 , halogen, -CN, -NO2, -OR, -SR, - R2, -Si(OH) 2 R, -Si(OH)(R) 2 , -Si(R) 3 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , -N(R)S(0) 2 R, -N(R)S(0) 2 R 2 , -P(0)(OR) 2 , -P(0)( R 2 )OR, or -P(0)( R 2
  • Ring B is selected from a 6-membered aryl containing 0-3 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; each R 3 is selected from hydrogen, deuterium, halogen, -CN, -N0 2 , -OR, -NR 2 , -SR, -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0)NR 2 , -C(0)NR(OR), -OC(0)R, -OC(0)NR 2 , -OP(0)(OR) 2 , -OP(0)(NR 2 ) 2 , -OP(0)(NR 2 ) 2 , -OP(0)(OR)NR 2 , -N(R)C(0)R, -N(R)C(0)OR, -N(R)C(0)NR 2 , -N(R)S(0) 2 R, -N(R)S(0) 2 NR 2
  • each R 4 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • R 5 is hydrogen, deuterium, an optionally substituted Ci-4 aliphatic, or -CN;
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)- , -Si(R) 2 - -Si(OH)(R)-, -Si(OH) 2 - -P(0)(OR)-, -P(0)(R)-, -P(0)( R 2 )-, -S-, - OC(O)-, -C(0)0- -C(O)-, -S(O)-, -S(0) 2 - -N(R) - -S(0) 2 N(R)- -N(R)C(0)-, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 3-8 membered saturated or partially unsaturated carbocyclylenyl, a 6-11 membered saturated or partially unsaturated spiro carbocyclylenyl, a 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-10 membered saturated or partially unsaturated heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur, a 6-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur, a 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated heterocyclylenyl having 1-4 heteroatoms independently
  • TBM is a target binding moiety
  • n 0, 1, or 2;
  • n 0, 1, 2, 3, or 4;
  • p is 0 or 1;
  • each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, deuterium, or an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of Formula III- A, III-B, or III-C:
  • aliphatic or "aliphatic group”, as used herein, means a straight-chain (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is completely saturated or that contains one or more units of unsaturation, or a monocyclic hydrocarbon or bicyclic hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic (also referred to herein as "carbocycle,” “cycloaliphatic” or “cycloalkyl”), that has a single point of attachment to the rest of the molecule.
  • aliphatic groups contain 1-6 aliphatic carbon atoms.
  • aliphatic groups contain 1-5 aliphatic carbon atoms. In other embodiments, aliphatic groups contain 1-4 aliphatic carbon atoms. In still other embodiments, aliphatic groups contain 1-3 aliphatic carbon atoms, and in yet other embodiments, aliphatic groups contain 1-2 aliphatic carbon atoms.
  • cycloaliphatic (or “carbocycle” or “cycloalkyl”) refers to a monocyclic C3-C6 hydrocarbon that is completely saturated or that contains one or more units of unsaturation, but which is not aromatic, that has a single point of attachment to the rest of the molecule.
  • Suitable aliphatic groups include, but are not limitation to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups and hybrids thereof such as (cycloalkyl)alkyl, (cycloalkenyl)alkyl or (cy cl oalkyl) alkenyl .
  • bridged bicyclic refers to any bicyclic ring system, i.e. carbocyclic or heterocyclic, saturated or partially unsaturated, having at least one bridge.
  • a "bridge” is an unbranched chain of atoms or an atom or a valence bond connecting two bridgeheads, where a "bridgehead” is any skeletal atom of the ring system which is bonded to three or more skeletal atoms (excluding hydrogen).
  • a bridged bicyclic group has 7-12 ring members and 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • bridged bicyclic groups are well known in the art and include those groups set forth below where each group is attached to the rest of the molecule at any substitutable carbon or nitrogen atom. Unless otherwise specified, a bridged bicyclic group is optionally substituted with one or more substituents as set forth for aliphatic groups. Additionally or alternatively, any substitutable nitrogen of a bridged bicyclic group is optionally substituted. Exemplary bridged bicyclics include:
  • lower alkyl refers to a C 1-4 straight or branched alkyl group.
  • exemplary lower alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
  • lower haloalkyl refers to a C 1-4 straight or branched alkyl group that is substituted with one or more halogen atoms.
  • heteroatom means one or more of oxygen, sulfur, nitrogen, phosphorus, or silicon (including, any oxidized form of nitrogen, sulfur, phosphorus, or silicon; the quaternized form of any basic nitrogen or; a substitutable nitrogen of a heterocyclic ring, for example N (as in 3,4-dihydro-2H-pyrrolyl), H (as in pyrrolidinyl) or R + (as in N-substituted pyrrolidinyl)).
  • Ci -8 saturated or unsaturated, straight or branched, hydrocarbon chain
  • bivalent Ci -8 or Ci-6) saturated or unsaturated, straight or branched, hydrocarbon chain
  • alkenylene or alkynylene chains that are straight or branched as defined herein.
  • alkylene refers to a bivalent alkyl group.
  • An "alkylene chain” is a polymethylene group, i.e., -(CH 2 )n-, wherein n is a positive integer, preferably from 1 to 6, from 1 to 4, from 1 to 3, from 1 to 2, or from 2 to 3.
  • a substituted alkylene chain is a polymethylene group in which one or more methylene hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
  • alkenylene refers to a bivalent alkenyl group.
  • a substituted alkenylene chain is a polymethylene group containing at least one double bond in which one or more hydrogen atoms are replaced with a substituent. Suitable substituents include those described below for a substituted aliphatic group.
  • cyclopropylenyl refers to a bivalent cyclopropyl group of
  • halogen means F, CI, Br, or I.
  • aryl used alone or as part of a larger moiety as in “aralkyl,” “aralkoxy,” or “aryloxyalkyl,” refers to monocyclic or bicyclic ring systems having a total of five to fourteen ring members, wherein at least one ring in the system is aromatic and wherein each ring in the system contains 3 to 7 ring members.
  • aryl may be used interchangeably with the term “aryl ring.”
  • aryl refers to an aromatic ring system which includes, but not limited to, phenyl, biphenyl, naphthyl, anthracyl and the like, which may bear one or more substituents.
  • aryl is a group in which an aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthimidyl, phenanthridinyl, or tetrahydronaphthyl, and the like.
  • heteroaryl and “heteroar-,” used alone or as part of a larger moiety, e.g., “heteroaralkyl,” or “heteroaralkoxy,” refer to groups having 5 to 10 ring atoms, preferably 5, 6, or 9 ring atoms; having 6, 10, or 14 ⁇ electrons shared in a cyclic array; and having, in addition to carbon atoms, from one to five heteroatoms.
  • heteroatom refers to nitrogen, oxygen, or sulfur, and includes any oxidized form of nitrogen or sulfur, and any quaternized form of a basic nitrogen.
  • Heteroaryl groups include, without limitation, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl.
  • heteroaryl and “heteroar-”, as used herein, also include groups in which a heteroaromatic ring is fused to one or more aryl, cycloaliphatic, or heterocyclyl rings, where the radical or point of attachment is on the heteroaromatic ring.
  • Nonlimiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-l,4-oxazin-3(4H)-one.
  • heteroaryl group may be mono- or bicyclic.
  • heteroaryl may be used interchangeably with the terms “heteroaryl ring,” “heteroaryl group,” or “heteroaromatic,” any of which terms include rings that are optionally substituted.
  • heteroarylkyl refers to an alkyl group substituted by a heteroaryl, wherein the alkyl and heteroaryl portions independently are optionally substituted.
  • heterocycle As used herein, the terms “heterocycle,” “heterocyclyl,” “heterocyclic radical,” and “heterocyclic ring” are used interchangeably and refer to a stable 5- to 7-membered monocyclic or 7-10-membered bicyclic heterocyclic moiety that is either saturated or partially unsaturated, and having, in addition to carbon atoms, one or more, preferably one to four, heteroatoms, as defined above.
  • nitrogen includes a substituted nitrogen.
  • the nitrogen may be N (as in 3,4-dihydro- 2H-pyrrolyl), H (as in pyrrolidinyl), or + R (as in N-substituted pyrrolidinyl).
  • a heterocyclic ring can be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure and any of the ring atoms can be optionally substituted.
  • saturated or partially unsaturated heterocyclic radicals include, without limitation, tetrahydrofuranyl, tetrahydrothiophenyl pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl, 2-oxa-6- azaspiro[3.3]heptane, and quinuclidinyl.
  • heterocycle refers to an alkyl group substituted by a heterocyclyl, wherein the alkyl and heterocyclyl portions independently are optionally substituted.
  • partially unsaturated refers to a ring moiety that includes at least one double or triple bond.
  • partially unsaturated is intended to encompass rings having multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties, as herein defined.
  • compounds of the invention may contain "optionally substituted” moieties.
  • substituted whether preceded by the term “optionally” or not, means that one or more hydrogens of the designated moiety are replaced with a suitable substituent.
  • an “optionally substituted” group may have a suitable substituent at each substitutable position of the group, and when more than one position in any given structure may be substituted with more than one substituent selected from a specified group, the substituent may be either the same or different at every position.
  • Combinations of substituents envisioned by this invention are preferably those that result in the formation of stable or chemically feasible compounds.
  • stable refers to compounds that are not substantially altered when subjected to conditions to allow for their production, detection, and, in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
  • Suitable monovalent substituents on R° are independently halogen, -(CH 2 )o- 2 R*, -(haloR"), -(CH 2 )o- 2 OH, -(CH 2 ) 0 - 2 OR", -(CH 2 ) 0 - 2 CH(OR") 2 ; -O(haloR'), -CN, -N 3 , -(CH 2 ) 0 - 2 C(0)R', -(CH 2 )o- 2 C(0)OH, -(CH 2 )o- 2 C(0)OR', -(CH 2 ) 0 - 2 SR', -(CH 2 ) 0 - 2 SH, -(CH 2 ) 0 - 2 NH 2 , - (CH 2 )o- 2 NHR e , -(CH 2 )o- 2 NR' 2
  • Suitable divalent substituents that are bound to vicinal substitutable carbons of an "optionally substituted” group include: -0(CR * 2 ) 2 - 3O-, wherein each independent occurrence of R * is selected from hydrogen, Ci-6 aliphatic which may be substituted as defined below, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable substituents on the aliphatic group of R * include halogen, -R", -(haloR"), -OH, -OR', -O(haloR'), -CN, -C(0)OH, -C(0)OR', - H 2 , -NHR", -NR' 2 , or -NO2, wherein each R" is unsubstituted or where preceded by "halo” is substituted only with one or more halogens, and is independently C1-4 aliphatic, -CH 2 Ph, -0(CH 2 )o-iPh, or a 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R ⁇ , - R ⁇ 2 , -C(0)R ⁇ , -C(0)OR ⁇ , -C(0)C(0)R ⁇ , -C(0)CH 2 C(0)R ⁇ , -S(0) 2 R ⁇ , -S(0) 2 R ⁇ 2 , -C(S) R ⁇ 2 , -C( H) R ⁇ 2 , or -N(R ⁇ )S(0) 2 R ⁇ ; wherein each R ⁇ is independently hydrogen, Ci- 6 aliphatic which may be substituted as defined below, unsubstituted -OPh, or an unsubstituted 5-6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or, notwithstanding the definition above, two independent occurrences of R ⁇ , taken together with their intervening atom(
  • Suitable substituents on the aliphatic group of R ⁇ are independently halogen, -R', -(haloR*), -OH, -OR', -O(haloR'), -CN, -C(0)OH, -C(0)OR', -NH 2 , -NHR', -NR' 2 , or -NO2, wherein each R* is unsubstituted or where preceded by "halo" is substituted only with one or more halogens, and is independently C1-4 aliphatic, -CH 2 Ph, -0(CH 2 )o-iPh, or a 5-6- membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
  • the term "pharmaceutically acceptable salt” refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge et al., describe pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 1977, 66, 1-19, incorporated herein by reference.
  • Pharmaceutically acceptable salts of the compounds of this invention include those derived from suitable inorganic and organic acids and bases.
  • Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid
  • organic acids such as acetic acid, oxalic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange.
  • salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphor sulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2- hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pec
  • Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and salts.
  • Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.
  • structures depicted herein are also meant to include all isomeric (e.g., enantiomeric, diastereomeric, and geometric (or conformational)) forms of the structure; for example, the R and S configurations for each asymmetric center, Z and E double bond isomers, and Z and E conformational isomers. Therefore, single stereochemical isomers as well as enantiomeric, diastereomeric, and geometric (or conformational) mixtures of the present compounds are within the scope of the invention. Unless otherwise stated, all tautomeric forms of the compounds of the invention are within the scope of the invention.
  • structures depicted herein are also meant to include compounds that differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures including the replacement of hydrogen by deuterium or tritium, or the replacement of a carbon by a 13 C- or 14 C-enriched carbon are within the scope of this invention.
  • Such compounds are useful, for example, as analytical tools, as probes in biological assays, or as therapeutic agents in accordance with the present invention.
  • a provided compound may be substituted with one or more deuterium atoms.
  • the term "binder” or “inhibitor” is defined as a compound that binds to CRBN and binds to or inhibits a targeted protein with measurable affinity.
  • an inhibitor has an IC50 and/or binding constant of less than about 50 ⁇ , less than about 1 ⁇ , less than about 500 nM, less than about 100 nM, less than about 10 nM, or less than about 1 nM.
  • a compound of the present invention may be tethered to a detectable moiety. It will be appreciated that such compounds are useful as imaging agents.
  • a detectable moiety may be attached to a provided compound via a suitable substituent.
  • suitable substituent refers to a moiety that is capable of covalent attachment to a detectable moiety.
  • moieties are well known to one of ordinary skill in the art and include groups containing, e.g., a carboxylate moiety, an amino moiety, a thiol moiety, or a hydroxyl moiety, to name but a few.
  • moieties may be directly attached to a provided compound or via a tethering group, such as a bivalent saturated or unsaturated hydrocarbon chain.
  • such moieties may be attached via click chemistry.
  • such moieties may be attached via a 1,3-cycloaddition of an azide with an alkyne, optionally in the presence of a copper catalyst.
  • Methods of using click chemistry are known in the art and include those described by Rostovtsev et al, Angew. Chem. Int. Ed. 2002, 41, 2596-99 and Sun et al., Bioconjugate Chem., 2006, 17, 52-57.
  • detectable moiety is used interchangeably with the term “label” and relates to any moiety capable of being detected, e.g., primary labels and secondary labels.
  • Primary labels such as radioisotopes (e.g., tritium, 32 P, 33 P, 35 S, or 14 C), mass-tags, and fluorescent labels are signal generating reporter groups which can be detected without further modifications.
  • Detectable moieties also include luminescent and phosphorescent groups.
  • secondary label refers to moieties such as biotin and various protein antigens that require the presence of a second intermediate for production of a detectable signal.
  • the secondary intermediate may include streptavidin-enzyme conjugates.
  • antigen labels secondary intermediates may include antibody-enzyme conjugates.
  • fluorescent label refers to moieties that absorb light energy at a defined excitation wavelength and emit light energy at a different wavelength.
  • fluorescent labels include, but are not limited to: Alexa Fluor dyes (Alexa Fluor 350, Alexa Fluor 488, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 633, Alexa Fluor 660 and Alexa Fluor 680), AMCA, AMCA-S, BODIPY dyes (BODIPY FL, BODIPY R6G, BODIPY TMR, BODIPY TR, BODIPY 530/550, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY 630/650, BODIPY 650/665), Carboxyrhodamine 6G, carboxy
  • mass-tag refers to any moiety that is capable of being uniquely detected by virtue of its mass using mass spectrometry (MS) detection techniques.
  • mass-tags include electrophore release tags such as N-[3-[4'-[(p- Methoxytetrafluorobenzyl)oxy]phenyl]-3-methylglyceronyl]isonipecotic Acid, 4'-[2,3,5,6- Tetrafluoro-4-(pentafluorophenoxyl)]methyl acetophenone, and their derivatives.
  • mass-tags include, but are not limited to, nucleotides, dideoxynucleotides, oligonucleotides of varying length and base composition, oligopeptides, oligosaccharides, and other synthetic polymers of varying length and monomer composition.
  • nucleotides dideoxynucleotides
  • oligonucleotides of varying length and base composition oligopeptides, oligosaccharides
  • other synthetic polymers of varying length and monomer composition.
  • a large variety of organic molecules, both neutral and charged (biomolecules or synthetic compounds) of an appropriate mass range (100-2000 Daltons) may also be used as mass-tags.
  • measurable affinity and “measurably modulate,” as used herein, means a measurable change in a CRBN activity between a sample comprising a compound of the present invention, or composition thereof, and CRBN, and an equivalent sample comprising CRBN, in the absence of said compound, or composition thereof.
  • the present invention provides a compound of formula I:
  • X 1 a bivalent moiety selected from a covalent bond, -CH 2 - -C(O)-, -C(S)-,
  • R is hydrogen, deuterium, halogen, -CN, OR, SR, -S(0)R, -S(0) 2 R, -NR 2 , or an optionally substituted Ci-4 aliphatic; each R 2 is independently hydrogen, -R 6 , halogen, -CN, -NO2, -OR, -SR, - R 2 , -S(0) 2 R, -S(0) 2 R 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • Ring B is a fused ring selected from 6-membered aryl containing 0-2 nitrogen atoms, 5 to 7- membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5- membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • R 3 is selected from hydrogen, halogen, -OR, -N(R) 2 , or -SR;
  • each R 4 is independently hydrogen, -R 6 , halogen, -CN, -NO2, -OR, -SR, - R 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • R 5 is hydrogen, C1-4 aliphatic, or -CN
  • each R 6 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)-, - S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) 2 -, -N(R)S(0) 2 -, -S(0) 2 N(R)-, -N(R)C(0)-, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen
  • TBM is a target binding moiety
  • n 0, 1, 2, 3 or 4;
  • each of n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of formula I':
  • X 1 is a bivalent moiety selected from a covalent bond, -CH 2 - -C(O)-, -C(S)-, or
  • R 1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, -S(0) 2 R, -NR 2 , or an optionally substituted Ci-4 aliphatic;
  • each R 2 is independently hydrogen, -R 6 , halogen, -CN, -N0 2 , -OR, -SR, -NR 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0)NR 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • Ring A is a bi- or tricy wherein Ring B is other than imidazo or benzo, ein Ring B is other than benzo, wherein Ring B is other than benz
  • Ring B is other than benzo
  • Ring B is a fused ring selected from 6-membered aryl containing 0-2 nitrogen atoms, 5 to 7- membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 5- membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur;
  • R 3 is selected from hydrogen, halogen, -OR, -N(R) 2 , or -SR;
  • each R 4 is independently hydrogen, -R 6 , halogen, -CN, -N0 2 , -OR, -SR, - R 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • R 5 is hydrogen, Ci-4 aliphatic, or -CN;
  • each R 6 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)-, - S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) 2 -, -N(R)S(0) 2 -, -S(0) 2 N(R)-, -N(R)C(0)-, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1 -2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen,
  • TBM is a target binding moiety
  • n 0, 1, 2, 3 or 4;
  • each of n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of formula I":
  • X 1 is a bivalent moiet selected from a covalent bond, -C(R) 2 - -C(O)-, -C(S)-, -P(0)(OR)-, -
  • X 2 is a carbon atom or silicon atom
  • X 3 is a bivalent moiety selected from -C(R) 2 - -N(R)-, -CF 2 - -CHF-, -S-, or -0-;
  • X 4 is a bivalent moiety selected from a covalent bond or -C(R) 2 -;
  • — is a single bond or double bond
  • R 1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, -S(0) 2 R, - R 2 , -P(0)(OR) 2 , -P(0)( R 2 )OR, -P(0)( R 2 ) 2 , -Si(OH) 2 R, -Si(OH)(R) 2 , -Si(R) 3 , an optionally substituted C 1-4 aliphatic, or:
  • R 1 and X 1 or X 4 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, carbocyclic ring or heterocyclic ring having 1-3 heteroatoms, independently selected from nitrogen, oxygen, or sulfur; each R 2 is independently hydrogen, deuterium, -R 6 , halogen, -CN, -N0 2 , -OR, -SR, -N(R) 2 , -Si(OH) 2 R, -Si(OH)(R) 2 , -Si(R) 3 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0)NR 2 , -C(0)N(R)OR, -OC(0)R, -OC(0)NR 2 , -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR,
  • Ring A i - or tricyclic ring selected from
  • Ring B is a fused ring selected from 6-membered aryl containing 0-3 nitrogen atoms, 5 to 7- membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5 -membered heteroaryl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur;
  • R 3 is selected from hydrogen, deuterium, halogen, -CN, -N0 2 , -OR, - R 2 , -SR, -S(0) 2 R, -S(0) 2 R 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0) R(OR), -OC(0)R, -OC(0) R 2 , -OP(0)(OR) 2 , -OP(0)( R 2 ) 2 , -OP(0)( R 2 ) 2 , -OP(0)( R 2 ) 2 , -OP(0)(OR) R 2 , -N(R)C(0)R, -N(R)C(0)OR, -N(R)C(0) R 2 , -N(R)S(0) 2 R, -N(R)S(0) 2 NR 2 , -N(R)P(0)(OR) 2 , -N(R)P(0)(OR) R 2 , -P(0)(OR)
  • each R 4 is independently hydrogen, deuterium, -R 6 , halogen, -S(0) 2 R, -S(0) 2 R 2; -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -P(0)(OR) 2 , -P(0)( R 2 )OR, or -P(0)( R 2 ) 2 ;
  • R 5 is hydrogen, deuterium, an optionally substituted C1-4 aliphatic, or -CN;
  • each R 6 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur;
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)- , -Si(R) 2 - -Si(OH)(R)-, -Si(OH) 2 - -C(H)(CF 3 )-, -P(0)(OR)-, -P(0)(R)-, -P(0)( R 2 )- , -S-, -OC(O)-, -C(0)0- -C(O)-, -S(O)-, -S(0) 2 - -N(R)S(0) 2 - - -, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-8 membered saturated or partially unsaturated carbocyclylenyl, a 6-1 1 membered saturated or partially unsaturated spiro carbocyclylenyl, a 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-10 membered saturated or partially unsaturated heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur, a 6-1 1 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur, a 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated heterocyclylenyl having 1-4 heteroatom
  • TBM is a target binding moiety
  • n 0, 1, 2, 3 or 4;
  • each of n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of formula II-A:
  • X 1 is a bivalent moiety selected from a covalent bond, -CH 2 - -C(O)-, -C(S)-, or is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, -S(0) 2 R, -NR 2 , or an optionally substituted C 1-4 aliphatic;
  • each R 2 is independently hydrogen, -R 4 , halogen, -CN, -N0 2 , -OR, -SR, -NR 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0)NR 2 , -C(0)N(R)OR, -OC(0)R, -OC(0)NR 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0)NR 2 , or -N(R)S(0) 2 R;
  • Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; each R 3 is independently hydrogen, -R 4 , halogen, -CN, -N0 2 , -OR, -SR, -NR 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0)NR 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • each R 4 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • R 5 is hydrogen, Ci-4 aliphatic, or -CN;
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)-, - S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) 2 -, -N( -, -S(0) 2 N(R -, -N(R)C(0)-, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1 -2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroaryl enyl having 1-4 heteroatoms independently selected from nitrogen
  • TBM is a target binding moiety
  • m is 0, 1, or 2;
  • n 0, 1, 2, 3, or 4;
  • p is 0 or 1, wherein when p is 0, the bond connecting Ring A and Ring B is connected to
  • each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of formula II'-A:
  • a bivalent moiety selected from a covalent bond, -CH 2 - -C(O)-, -C(S)-,
  • Ci-4 aliphatic is hydrogen, deuterium, halogen, -CN, OR, SR, -S(0)R, -S(0) 2 R, -NR 2 , or an optionally substituted Ci-4 aliphatic; Ring - or bicyclic ring selected from
  • each R 2 is independently hydrogen, -R 4 , halogen, -CN, -NO2, -OR, -SR, - R 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; each R 3 is independently hydrogen, -R 4 , halogen, -CN, -NO2, -OR, -SR, -NR 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0)NR 2 , -C(0)N(R)OR, -OC(0)R, -OC(0)NR 2 , -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0)NR 2 , or -N(R)S(0) 2 R;
  • each R 4 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • R 5 is hydrogen, C 1-4 aliphatic, or -CN;
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)-, - S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) 2 -, -N( -, -S(0) 2 N(R -, -N(R)C(0)-, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1 -2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroaryl enyl having 1-4 heteroatoms independently selected from nitrogen
  • TBM is a target binding moiety
  • n 0, 1, or 2;
  • each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of Formula II"-A:
  • X 1 is ivalent moiety selected from a covalent bond, -C(R) 2 - -C(O)-, -C(S)-, -P(0)(OR)-, -
  • X 2 is a carbon atom or silicon atom
  • X 3 is a bivalent moiety selected from -C(R) 2 - -N(R)-, -CF 2 - -CHF-, -S-, or -0-;
  • X 4 is a bivalent moiety selected from a covalent bond or -C(R) 2 -;
  • — is a single bond or double bond
  • R 1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, -S(0) 2 R, - R 2 , -P(0)(OR) 2 , -P(0)( R 2 )OR, -P(0)( R 2 ) 2 , -Si(OH) 2 R, -Si(OH)(R) 2 , -Si(R) 3 , an optionally substituted Ci-4 aliphatic, or: R 1 and X 1 or X 4 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, carbocyclic ring or heterocyclic ring having 1-3 heteroatoms, independently selected from nitrogen, oxygen, or sulfur;
  • each R 2 is independently hydrogen, deuterium, -R 4 , halogen, -CN, -N0 2 , -OR, -SR, -N(R) 2 , -Si(OH) 2 R, -Si(OH)(R) 2 , -Si(R) 3 , -S(0) 2 R, -S(0) 2 R 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , -N(R)S(0) 2 R, -N(R)S(0) 2 R 2 , -P(0)(OR) 2 , -P(0)( R 2 )OR, or -P(0)( R 2 ) 2 ;
  • Ring B is selected from a 6-membered aryl containing 0-3 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur; each R 3 is selected from hydrogen, deuterium, -R 4 , halogen, -CN, -NO2, -OR, -NR 2 , -SR, -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0) R(OR), -OC(0)R, -OC(0) R 2 , -OP(0)(OR) 2 , -OP(0)( R 2 ) 2 , -OP(0)( R 2 ) 2 , -OP(0)( R 2 ) 2 , -OP(0)(OR) R 2 , -N(R)C(0)R, -N(R)C(0)OR, -N(R)C(0) R 2 ,
  • each R 4 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • R 5 is hydrogen, deuterium, an optionally substituted C1-4 aliphatic, or -CN;
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)- , -Si(R) 2 - -Si(OH)(R)-, -Si(OH) 2 - -P(0)(OR)-, -P(0)(R)-, -P(0)(NR 2 )-, -S-, - OC(O)-, -C(0)0- -C(O)-, -S(O)-, -S(0) 2 - -N(R) - -S(0) 2 N(R)- -N(R)C(0)-, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 3-8 membered saturated or partially unsaturated carbocyclylenyl, a 6-11 membered saturated or partially unsaturated spiro carbocyclylenyl, a 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-10 membered saturated or partially unsaturated heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur, a 6-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur, a 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated heterocyclylenyl having 1 -4 heteroatoms
  • TBM is a target binding moiety
  • n 0, 1, or 2;
  • n 0, 1, 2, 3, or 4;
  • p is 0 or 1, wherein when p is 0, the bond connecting Ring A and Ring B is connected to
  • each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci-6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of formula II-B:
  • X 1 is a bivalent moiety selected from a covalent bond, -CH 2 - R 1 is hydrogen, deuterium, halogen,
  • each R 2 is independently hydrogen, -R 4 , halogen, -CN, -NO2, -OR, -SR, - R 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; each R 3 is independently hydrogen, -R 4 , halogen, -CN, -NO2, -OR, -SR, -NR 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0)NR 2 , -C(0)N(R)OR, -OC(0)R, -OC(0)NR 2 , -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0)NR 2 , or -N(R)S(0) 2 R;
  • each R 4 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • R 5 is hydrogen, C1-4 aliphatic, or -CN
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)-, - S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) 2 -, -N(R)S(0) 2 -, -S(0) 2 N(R)-, -N(R)C(0)-, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen
  • TBM is a target binding moiety
  • n 0, 1, or 2;
  • n 0, 1, 2, 3, or 4;
  • p is 0 or 1;
  • each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of formula II'-
  • a bivalent moiety selected from a covalent bond, -CH 2 - is hydrogen, deuterium, halogen,
  • each R 2 is independently hydrogen, -R 4 , halogen, -CN, -NO2, -OR, -SR, - R 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , or -N(R)S(0) 2 R;
  • Ring B is selected from a 6-membered aryl containing 0-2 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from nitrogen, oxygen or sulfur; each R 3 is independently hydrogen, -R 4 , halogen, -CN, -NO2, -OR, -SR, -NR 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0)NR 2 , -C(0)N(R)OR, -OC(0)R, -OC(0)NR 2 , -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0)NR 2 , or -N(R)S(0) 2 R;
  • each R 4 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • R 5 is hydrogen, C1-4 aliphatic, or -CN
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)-, - S-, -OC(O)-, -C(0)0-, -C(O)-, -S(O)-, -S(0) 2 -, -N(R)S(0) 2 -, -S(0) 2 N(R)-, -N(R)C(0)-, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 4-7 membered saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated spiro carbocyclylenyl, an 8-10 membered bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-7 membered saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 4-7 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, an 8-10 membered bicyclic saturated or partially unsaturated heterocyclylenyl having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen
  • TBM is a target binding moiety
  • n 0, 1, or 2;
  • n 0, 1, 2, 3, or 4;
  • p is 0 or 1;
  • each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, or an optionally substituted group selected from Ci aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • the present invention provides a compound of Formula II"-B:
  • X 1 is a bivalent moiety selected from a covalent bond -C(R) 2 - -C(O)-, -C(S)-, -P(0)(OR)-, -
  • X 2 is a carbon atom or silicon atom
  • X 3 is a bivalent moiety selected from -C(R) 2 - -N(R)-, -CF 2 - -CHF-, -S-, or -0-;
  • X 4 is a bivalent moiety selected from a covalent bond or -C(R) 2 -;
  • — is a single bond or double bond
  • R 1 is hydrogen, deuterium, halogen, -CN, -OR, -SR, -S(0)R, -S(0) 2 R, - R 2 , -P(0)(OR) 2 , -P(0)( R 2 )OR, -P(0)( R 2 ) 2 , -Si(OH) 2 R, -Si(OH)(R) 2 , -Si(R) 3 , an optionally substituted C1-4 aliphatic, or:
  • R 1 and X 1 or X 4 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, carbocyclic ring or heterocyclic ring having 1-3 heteroatoms, independently selected from nitrogen, oxygen, or sulfur;
  • each R 2 is independently hydrogen, deuterium, -R 6 , halogen, -CN, -NO2, -OR, -SR, - R2, -Si(OH) 2 R, -Si(OH)(R) 2 , -Si(R) 3 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , -N(R)S(0) 2 R, -N(R)S(0) 2 R 2 , -P(0)(OR) 2 , -P(0)( R 2 )OR, or -P(0)( R 2
  • Ring B is selected from a 6-membered aryl containing 0-3 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur;
  • each R 3 is selected from hydrogen, deuterium, -R 4 , halogen, -CN, -NO2, -OR, -NR 2 , -SR, -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0)NR 2 , -C(0)NR(OR), -OC(0)R, -OC(0)NR 2 , -OP(0)(OR) 2 , -OP(0)(NR 2 ) 2 , -OP(0)(NR 2 ) 2 , -OP(0)(OR)NR 2 , -N(R)C(0)R, -N(R)C(0)OR, -N(R)C(0)NR 2 , -N(R)S(0) 2 R, -N(R)S(0) 2 NR 2 , -N(R)P(0)(OR) 2 , -N(R)P(0)(OR) R 2 , -N(R)P(0)(OR) R 2
  • each R 4 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4- 7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur;
  • R 5 is hydrogen, deuterium, an optionally substituted Ci-4 aliphatic, or -CN;
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy-, -0-, -N(R)- , -Si(R) 2 - -Si(OH)(R)-, -Si(OH) 2 - -P(0)(OR)-, -P(0)(R)-, -P(0)( R 2 )-, -S-, - OC(O)-, -C(0)0- -C(O)-, -S(O)-, -S(0) 2 - -N(R) - -S(0) 2 N(R)- -N(R)C(0)-, -
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 3-8 membered saturated or partially unsaturated carbocyclylenyl, a 6-11 membered saturated or partially unsaturated spiro carbocyclylenyl, a 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-10 membered saturated or partially unsaturated heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur, a 6-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur, a 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated heterocyclylenyl having 1-4 heteroatoms independently
  • TBM is a target binding moiety
  • n 0, 1, or 2;
  • n 0, 1, 2, 3, or 4;
  • p is 0 or 1;
  • each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10;
  • each R is independently hydrogen, deuterium, or an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur, or:
  • X 1 is a bivalent moiety selected from a covalent bond -CH 2 - -C(R) 2 - -C(O)-, -C(S)-, -CH(R)-, -CH(CF 3 )-, -P(0)(OR)-, -P(0)(R)-, -
  • X 1 is a covalent bond. In some embodiments, X 1 is -CH 2 - In some embodiments, X 1 is -C(R) 2 - In some embodiments, X 1 is -C(O)-. In some embodiments, X 1 is -C(S)-. In some embodiments, X 1 is -CH(R)-. In some embodiments, X 1 is -CH(CF 3 )-. In some embodiments, X 1 is -P(0)(OR)-. In some embodiments, X 1 is -P(0)(R)-. In some embodiments, X 1 is -P(0)( R 2 )-. In som mbodiments, X 1 is -S(O)-. In some embodiments, X 1 is -S(O)-. In some embodiments, X 1
  • X 1 i is [0080] In some embodiments, X 1 is selected from those depicted in Table 1, below.
  • X 2 is a carbon atom or silicon atom.
  • X 2 is a carbon atom. In some embodiments, X 2 is a silicon atom.
  • X 2 is selected from those depicted in Table 1, below.
  • X 3 is a bivalent moiety selected from -CH 2 -
  • X 3 is -CH 2 - In some embodiments, X 1 is -C(R) 2 - In some embodiments, X 3 is -N(R)-. In some embodiments, X 3 is -CF 2 - In some embodiments, X 3 is - CHF-. In some embodiments, X 3 is -S-. In some embodiments, X 3 is -CH(R)-. In some embodiments, X 3 is -0-.
  • X 3 is selected from those depicted in Table 1, below.
  • X 4 is a bivalent moiety selected from a covalent bond, -CH 2 - or -C(R) 2 -.
  • X 4 is a covalent bond. In some embodiments, X 4 is -CH 2 - In some embodiments, X 4 is -C(R) 2 -
  • X 4 is selected from those depicted in Table 1, below.
  • R 1 is hydrogen, deuterium, halogen, -CN, - OR, -SR, -S(0)R, -S(0) 2 R, - R 2 , -P(0)(OR) 2 , -P(0)( R 2 )OR, -P(0)( R 2 ) 2 , -Si(OH) 2 R, -Si(OH)(R) 2 , -Si(R) 3 , an optionally substituted Ci-4 aliphatic, or R 1 and X 1 or X 4 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, carbocyclic ring or heterocyclic ring having 1-3 heteroatoms, independently selected from nitrogen, oxygen, or sulfur.
  • R 1 is hydrogen. In some embodiments, R 1 is deuterium. In some embodiments, R 1 is halogen. In some embodiments, R 1 is -CN. In some embodiments, R 1 is -OR. In some embodiments, R 1 is -SR. In some embodiments, R 1 is -S(0)R. In some embodiments, R 1 is -S(0) 2 R. In some embodiments, R 1 is -NR 2 . In some embodiments, R 1 is - P(0)(OR) 2 . In some embodiments, R 1 is -P(0)(NR 2 )OR. In some embodiments, R 1 is - P(0)(NR 2 ) 2 . In some embodiments, R 1 is -Si(OH) 2 R.
  • R 1 is -Si(OH)(R) 2 . In some embodiments, R 1 is -Si(R) 3 . In some embodiments, R 1 is an optionally substituted Ci-4 aliphatic. In some embodiments, R 1 and X 1 or X 4 are taken together with their intervening atoms to form a 5-7 membered saturated, partially unsaturated, carbocyclic ring or heterocyclic ring having 1 -3 heteroatoms, independently selected from nitrogen, oxygen, or sulfur.
  • R 1 is selected from those depicted in Table 1, below.
  • each R 2 is independently hydrogen, deuterium, -R 6 , halogen, -CN, -N0 2 , -OR, -SR, -N(R) 2 , -Si(OH) 2 R, -Si(OH)(R) 2 , -Si(R) 3 , -S(0) 2 R, - S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , - N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , -N(R)S(0) 2 R, -N(R)S(0) 2 R 2 , -P(0)(OR) 2 , - P(0)( R 2 )OR, or -P(0)( R 2 ) 2 .
  • R 2 is hydrogen. In some embodiments, R 2 is deuterium. In some embodiments, R 2 is -R 6 . In some embodiments, R 2 is halogen. In some embodiments, R 2 is -CN. In some embodiments, R 2 is -N0 2 . In some embodiments, R 2 is -OR. In some embodiments, R 2 is -Si(OH) 2 R. In some embodiments, R 2 is -Si(OH)(R) 2 . In some embodiments, R 2 is -SR. In some embodiments, R 2 is -NR 2 . In some embodiments, R 2 is -Si(R) 3 . In some embodiments, R 2 is -S(0) 2 R.
  • R 2 is -S(0) 2 NR 2 . In some embodiments, R 2 is -S(0)R. In some embodiments, R 2 is -C(0)R. In some embodiments, R 2 is -C(0)OR. In some embodiments, R 2 is -C(0)NR 2 . In some embodiments, R 2 is -C(0)N(R)OR. In some embodiments, R 2 is -OC(0)R. In some embodiments, R 2 is -OC(0)NR 2 . In some embodiments, R 2 is -N(R)C(0)OR. In some embodiments, R 2 is -N(R)C(0)R. In some embodiments, R 2 is -N(R)C(0)NR 2 .
  • R 2 is -N(R)S(0) 2 R. In some embodiments, R 2 is -P(0)(OR) 2 . In some embodiments, R 2 is -P(0)(NR 2 )OR. In some embodiments, R 2 is -P(0)(NR 2 ) 2 .
  • R 2 is selected from those depicted in Table 1, below.
  • Ring A is a bi- or tricyclic ring selected from
  • Ring A is embodiments, Ring A is me embodiments, Ring A is . In some embodiments, Ring A is some embodiments, Ring A is odiments, Ring A is NR°
  • Ring A is . In some embodiments, Ring A is ome embodiments, Rin
  • Ring A is In some embodiments,
  • Ring A is . i n some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is .
  • Ring A is . In some embodiments, Ring A is In some embodiments, Ring A is In some embodiments, Ring A is In some embodiments Rin A is In some embodiments, Ring A is T Inn s soommee e emmbbooddii .mmeennttss R Rii.nngcr A A i i.ss . In some embodiments,
  • Ring A is In some embodiments, Ring A is In some embodiments, Ring A is In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is In some embodiments, Ring A is In some embodiments,
  • Ring A is In some embodiments, Ring A is
  • Ring A is embodiments, Ring A is
  • Ring A is ome embodiments, Ring ome embodiments, Ring A is . In some embodiments,
  • Ring A is selected from those depicted in Table 1, below.
  • Ring B is a fused ring selected from 6- membered aryl containing 0-3 nitrogen atoms, 5 to 7-membered partially saturated carbocyclyl, 5 to 7-membered partially saturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur, or 5-membered heteroaryl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur.
  • Ring B is a 6-membered aryl containing 0-3 nitrogen atoms.
  • Ring B is a 5 to 7-membered partially saturated carbocyclyl.
  • Ring B is 5 to 7-membered partially saturated heterocyclyl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur. In some embodiments, Ring B is 5-membered heteroaryl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, or sulfur. ome embodiments, Ring B is some embodiments, Ring B is In some embodiments, Ring
  • each Ring B is In some embodiments, each
  • Ring B is some embodiments, Ring B is In some embodiments, Ring B In some embodiments, Ring B In some embodiments, Ring B is . In some embodiments, Ring B is n some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is In some embodiments, Ring B is some embodiments, Ring B is . In some embodiments, Ring B is In some embodiments, Ring B is . In some embodiments, Ring B is . In some embodiments, Ring B is
  • Ring B is selected from those depicted in Table 1, below.
  • — is a single bond. In some embodiments,— is a double bond.
  • — is selected from those depicted in Table 1, below.
  • R 3 is hydrogen, deuterium, halogen, -CN, - N0 2 , -OR, - R 2 , -SR, -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0) R(OR), -OC(0)R, -OC(0) R 2 , -OP(0)(OR) 2 , -OP(0)( R 2 ) 2 , -OP(0)( R 2 ) 2 , -OP(0)( R 2 ) 2 , -OP(0)(OR) R 2 , -N(R)C(0)R, -N(R)C(0)OR, -N(R)C(0) R 2 , -N(R)S(0) 2 R, -N(R)S(0) 2 NR 2 , -N(R)P(0)(OR) 2 , -N(R)P(0)(OR) R 2 , -P(0)(OR) R
  • R 3 is hydrogen. In some embodiments, R 3 is deuterium. In some embodiments, R 3 is halogen. In some embodiments, R 3 is -CN. In some embodiments, R 3 is -N0 2 . In some embodiments, R 3 is -OR. In some embodiments, R 3 is -NR 2 . In some embodiments, R 3 is -SR. In some embodiments, R 3 is -S(0) 2 R. In some embodiments, R 3 is - S(0) 2 NR 2 . In some embodiments, R 3 is -S(0)R. In some embodiments, R 3 is -C(0)R. In some embodiments, R 3 is -C(0)OR.
  • R 3 is -C(0)NR 2 . In some embodiments, R 3 is -C(0)NR(OR). In some embodiments, R 3 is -OC(0)R. In some embodiments, R 3 is -OC(0)NR 2 . In some embodiments, R 3 is -OP(0)(OR) 2 . In some embodiments, R 3 is -OP(0)(NR 2 ) 2 . In some embodiments, R 3 is -OP(0)(OR)NR 2 . In some embodiments, R 3 is -N(R)C(0)R. In some embodiments, R 3 is -N(R)C(0)OR. In some embodiments, R 3 is -N(R)C(0)NR 2 .
  • R 3 is -N(R)S(0) 2 R. In some embodiments, R 3 is -N(R)S(0) 2 NR 2 . In some embodiments, R 3 is -N(R)P(0)(OR) 2 . In some embodiments, R 3 is -N(R)P(0)(OR) R 2 . In some embodiments, R 3 is -P(0)(OR) 2 . In some embodiments, R 3 is -P(0)( R 2 )OR. In some embodiments, R 3 is -P(0)(NR 2 ) 2 . In some embodiments, R 3 is -Si(OH) 2 R. In some embodiments, R 3 is -Si(OH)(R) 2 . In some embodiments, R 3 is -Si(R) 3 .
  • R 3 is methyl. In some embodiments, R 3 is -OCH 3 . In some embodiments, R 3 is chloro.
  • R 3 is selected from those depicted in Table 1, below.
  • each R 4 is independently hydrogen, deuterium, -R 6 , halogen, -CN, -N0 2 , -OR, -SR, - R 2 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , -N(R)S(0) 2 R, -P(0)(OR) 2 , -P(0)( R 2 )OR, or -P(0)( R 2 ) 2 .
  • R 4 is hydrogen. In some embodiments, R 4 is -R 6 . In some embodiments, R 4 is halogen. In some embodiments, R 4 is -CN. In some embodiments, R 4 is - N0 2 . In some embodiments, R 4 is -OR. In some embodiments, R 4 is -SR. In some embodiments, R 4 is -NR 2 . In some embodiments, R 4 is -S(0) 2 R. In some embodiments, R 4 is -S(0) 2 NR 2 . In some embodiments, R 4 is -S(0)R. In some embodiments, R 4 is -C(0)R. In some embodiments, R 4 is -C(0)OR.
  • R 4 is -C(0)NR 2 . In some embodiments, R 4 is - C(0)N(R)OR. In some embodiments, R 4 is -OC(0)R. In some embodiments, R 4 is -OC(0)NR 2 . In some embodiments, R 4 is -N(R)C(0)OR. In some embodiments, R 4 is -N(R)C(0)R. In some embodiments, R 4 is -N(R)C(0)NR 2 . In some embodiments, R 4 is -N(R)S(0) 2 R. In some embodiments, R 4 is -P(0)(OR) 2 . In some embodiments, R 4 is -P(0)(NR 2 )OR. In some embodiments, R 4 is -P(0)(NR 2 ) 2 .
  • R 4 is methyl. In some embodiments, R 4 is ethyl. In some embodiments, R 4 is cyclopropyl.
  • R 4 is selected from those depicted in Table 1, below.
  • R 5 is hydrogen, deuterium, an optionally substitute C 1-4 aliphatic, or -CN.
  • R 5 is hydrogen. In some embodiments, R 5 is deuterium. In some embodiments, R 5 is an optionally substituted C 1-4 aliphatic. In some embodiments, R 5 is - CN.
  • R 5 is selected from those depicted in Table 1, below.
  • each R 6 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur.
  • R 6 is an optionally substituted Ci-6 aliphatic. In some embodiments, R 6 is an optionally substituted phenyl. In some embodiments, R 6 is an optionally substituted 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur. In some embodiments, R 6 is an optionally substituted 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur.
  • R 6 is selected from those depicted in Table 1, below.
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy- -0-, -N(R)-, -Si(R) 2 - -Si(OH)(R)-, -Si(OH) 2 - -P(0)(OR)-, -P(0)(R)-, -P(0)( R 2 )-, -S-, -OC(O)-, -C(0)0- -C(O)-, -S(O)-, -S(0) 2 - - - - - -
  • L is a covalent bond.
  • L is a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy- -0-, -N(R)-, -Si(R) 2 - -Si(OH)(R)-, -Si(OH) 2 - , -P(0)(OR)-, -P(0)(R)-, -P(0)( R 2 )-, -S-, -OC(O)-, -C(0)0- -C(O)-, -S(O)-, -S(0) 2 - - N(R)S(0) 2 - -S(0) 2 N(R)-, -N(R)C(0)-, -C(0)N(R)-, -OC(0)N(R)-, -N(R)C(0)0-,
  • L is In some embodiments, L is In some embodiments, L is In some embodiments, L is In some embodiments, L is In some embodiments, L is In some embodiments, L is In some
  • L is embodiments, L is s [00129] In some embodiments, L is In some embodiments, L is In some embodiments, L
  • L is some embodiments
  • L is In some embodiments, L is In some embodiments, L is In some embodiments, L is
  • L is selected from those depicted in Table 1, below.
  • each -Cy- is independently an optionally substituted bivalent ring selected from phenylenyl, an 8-10 membered bicyclic arylenyl, a 3-8 membered saturated or partially unsaturated carbocyclylenyl, a 6-11 membered saturated or partially unsaturated spiro carbocyclylenyl, a 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated carbocyclylenyl, a 4-10 membered saturated or partially unsaturated heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur, a 6-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur, a 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated heterocyclyl,
  • -Cy- is an optionally substituted bivalent ring selected from phenylenyl. In some embodiments, -Cy- is an optionally substituted 8-10 membered bicyclic arylenyl. In some embodiments, -Cy- is an optionally substituted 3-8 membered saturated or partially unsaturated carbocyclylenyl. In some embodiments, -Cy- is an optionally substituted 6- 11 membered saturated or partially unsaturated spiro carbocyclylenyl. In some embodiments, - Cy- is an optionally substituted 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated carbocyclylenyl.
  • -Cy- is an optionally substituted 4- 10 membered saturated or partially unsaturated heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur.
  • -Cy- is an optionally substituted 6-11 membered saturated or partially unsaturated spiro heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur.
  • -Cy- is an optionally substituted 5-12 membered bridged or unbridged bicyclic saturated or partially unsaturated heterocyclylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur.
  • -Cy- is an optionally substituted 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur, or an 8-10 membered bicyclic heteroarylenyl having 1-5 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, phosphorus, or sulfur.
  • -Cy- is selected from those depicted in Table 1, below.
  • TBM is a target binding moiety.
  • TBM is a target binding moiety.
  • TBM binds to a protein selected from those listed in paragraph
  • TBM is selected from one of the drugs listed in Table 2, wherein
  • the drug is attached to at any modifiable carbon, oxygen, sulfur or nitrogen atom.
  • TBM is selected from one of the drugs listed in Table 2, wherein
  • TBM is selected from one of the dru s listed in Table 2, wherein
  • the drug is attached to at any modifiable carbon, oxygen, sulfur or nitrogen atom.
  • TBM is selected from one of the drugs listed in Table 2, wherein
  • the drug is attached to at any modifiable carbon, oxygen, sulfur or nitrogen atom.
  • TBM In some embodiments, TBM
  • TBM is In some embodiments, TBM is . In some
  • TBM is selected from those depicted in Table 1, below.
  • n 0, 1, 2, 3 or 4.
  • m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4.
  • m is selected from those depicted in Table 1, below.
  • each n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7. In some embodiments, n is 8. In some embodiments, n is 9. In some embodiments, n is 10.
  • n is selected from those depicted in Table 1, below.
  • each R is independently hydrogen, deuterium, or an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur, or two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from boron, nitrogen, oxygen, silicon, and sulfur.
  • R is hydrogen. In some embodiments, R is deuterium. In some embodiments, R is optionally substituted Ci- 6 aliphatic. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is optionally substituted 4-7 membered saturated or partially unsaturated heterocyclic having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur. In some embodiments, R is optionally substituted 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur.
  • two R groups on the same nitrogen are taken together with their intervening atoms to form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having 0-3 heteroatoms, in addition to the nitrogen, independently selected from boron, nitrogen, oxygen, silicon, and sulfur.
  • R is selected from those depicted in Table 1, below.
  • the present invention provides a compound of formula II-A or II-B, wherein X 1 , R 1 , R 5 , R, -Cy- and TBM are recited as for formula I as above and herein, and Ring A, Ring B, R 2 , R 3 , R 4 , L, m, n, p, and q are recited as for formula II-A and II-B as below and herein.
  • Ring A is a mono- or bicyclic ring selected
  • Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is In some embodiments, Ring embodiments, Ring A is In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is .
  • Ring A is e embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring
  • Ring A is . In some embodiments, Ring A is O In some embodiments, Ring A is in some embodiments, Ring A is 00156] In some embodiments, Ring A is . In some embodiments, Ring A is ome embodiments, Ring . In some embodiments, Ring A is . In some embodiments,
  • Ring A is . In some embodiments, Ring A is In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, Ring A is .
  • Ring A is in some embodiments, Ring A is . In some embodiments, Ring A is . In some embodiments, embodiment , Ring A is .
  • Ring A is a mono- or bicyclic ring selected from
  • Ring A is selected from those depicted in Table 1, below.
  • each R 2 is independently hydrogen, deuterium, -R 4 , halogen, -CN, -N0 2 , -OR, -SR, - R 2 , -Si(OH) 2 R, -Si(OH)(R) 2 , -Si(R) 3 , -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, -C(0) R 2 , -C(0)N(R)OR, -OC(0)R, -OC(0) R 2 , -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0)OR, -N(R)C(0)R, -N(R)C(0) R 2 , -N(R)S(0) 2 R, -N(R)S(0) 2 R 2 , -P(0)(OR) 2 , -P(0)( R 2 )OR, or -P(0)( R 2 ) 2
  • R 2 is hydrogen. In some embodiments, R 2 is deuterium. In some embodiments, R 2 is -R 4 . In some embodiments, R 2 is halogen. In some embodiments, R 2 is -CN. In some embodiments, R 2 is -N0 2 . In some embodiments, R 2 is -OR. In some embodiments, R 2 is -Si(OH) 2 R. In some embodiments, R 2 is -Si(OH)(R) 2 . In some embodiments, R 2 is -SR. In some embodiments, R 2 is -NR 2 . In some embodiments, R 2 is -Si(R) 3 . In some embodiments, R 2 is -S(0) 2 R.
  • R 2 is -S(0) 2 NR 2 . In some embodiments, R 2 is -S(0)R. In some embodiments, R 2 is -C(0)R. In some embodiments, R 2 is -C(0)OR. In some embodiments, R 2 is -C(0)NR 2 . In some embodiments, R 2 is -C(0)N(R)OR. In some embodiments, R 2 is -OC(0)R. In some embodiments, R 2 is -OC(0)NR 2 . In some embodiments, R 2 is -N(R)C(0)OR. In some embodiments, R 2 is -N(R)C(0)R. In some embodiments, R 2 is -N(R)C(0)NR 2 .
  • R 2 is -N(R)S(0) 2 R. In some embodiments, R 2 is -P(0)(OR) 2 . In some embodiments, R 2 is -P(0)( R 2 )OR. In some embodiments, R 2 is -P(0)( R 2 ) 2 .
  • R 2 is methyl
  • R 2 is selected from those depicted in Table 1, below.
  • Ring B is selected from a 6-membered aryl containing 0-3 nitrogen atoms or a 5-membered heteroaryl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur.
  • Ring B is a 6-membered aryl containing 0-3 nitrogen atoms. In some embodiments, Ring B is a 5-membered heteroaryl with 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur.
  • Ring B is selected from those depicted in Table 1, below.
  • each R 3 is independently hydrogen, deuterium, halogen, -CN, -N0 2 , -OR, - R 2 , -SR, -S(0) 2 R, -S(0) 2 NR 2 , -S(0)R, -C(0)R, -C(0)OR, - C(0) R 2 , -C(0) R(OR), -OC(0)R, -OC(0) R 2 , -OP(0)(OR) 2 , -OP(0)( R 2 ) 2 , -OP(0)( R 2 ) 2 , -OP(0)( R 2 ) 2 , -OP(0)(OR) R 2 , -N(R)C(0)R, -N(R)C(0)OR, -N(R)C(0) R 2 , -N(R)S(0) 2 R, -N(R)S(0) 2 NR 2 , -N(R)P(0)(OR) 2 , -N(R)P(0)(OR) R 2 , -P(0)(OR
  • R 3 is hydrogen. In some embodiments, R 3 is deuterium. In some embodiments, R 3 is halogen. In some embodiments, R 3 is -CN. In some embodiments, R 3 is -N0 2 . In some embodiments, R 3 is -OR. In some embodiments, R 3 is -NR 2 . In some embodiments, R 3 is -SR. In some embodiments, R 3 is -S(0) 2 R. In some embodiments, R 3 is - S(0) 2 NR 2 . In some embodiments, R 3 is -S(0)R. In some embodiments, R 3 is -C(0)R. In some embodiments, R 3 is -C(0)OR.
  • R 3 is -C(0)NR 2 . In some embodiments, R 3 is -C(0)NR(OR). In some embodiments, R 3 is -OC(0)R. In some embodiments, R 3 is -OC(0)NR 2 . In some embodiments, R 3 is -OP(0)(OR) 2 . In some embodiments, R 3 is -OP(0)(NR 2 ) 2 . In some embodiments, R 3 is -OP(0)(OR)NR 2 . In some embodiments, R 3 is -N(R)C(0)R. In some embodiments, R 3 is -N(R)C(0)OR. In some embodiments, R 3 is -N(R)C(0)NR 2 .
  • R 3 is -N(R)S(0) 2 R. In some embodiments, R 3 is -N(R)S(0) 2 NR 2 . In some embodiments, R 3 is -N(R)P(0)(OR) 2 . In some embodiments, R 3 is -N(R)P(0)(OR)NR 2 . In some embodiments, R 3 is -P(0)(OR) 2 . In some embodiments, R 3 is -P(0)( R2)OR. In some embodiments, R 3 is -P(0)(NR 2 ) 2 . In some embodiments, R 3 is - Si(OH)2R. In some embodiments, R 3 is -Si(OH)(R)2. In some embodiments, R 3 is -Si(R) 3 .
  • R 3 is selected from those depicted in Table 1, below.
  • each R 4 is independently an optionally substituted group selected from Ci- 6 aliphatic, phenyl, a 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur.
  • R 4 is an optionally substituted Ci-6 aliphatic. In some embodiments, R 4 is an optionally substituted phenyl. In some embodiments, R 4 is an optionally substituted 4-7 membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur. In some embodiments, R 4 is an optionally substituted 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from boron, nitrogen, oxygen, silicon, and sulfur.
  • R 4 is methyl
  • R 4 is selected from those depicted in Table 1, below.
  • L is a covalent bond or a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy- -0-, -N(R)-, -Si(R) 2 - -Si(OH)(R)-, -Si(OH) 2 - -P(0)(OR)-, -P(0)(R)-, -P(0)( R 2 )-, -S-, -OC(O)-, -C(0)0- -C(O)-, -S(O)-, -S(0) 2 - -N(R)S(0) 2 - - -
  • L is a covalent bond.
  • L is a bivalent, saturated or unsaturated, straight or branched Ci-50 hydrocarbon chain, wherein 0-6 methylene units of L are independently replaced by -Cy- -0-, -N(R)-, -Si(R) 2 - -Si(OH)(R)-, -Si(OH) 2 - , -P(0)(OR)-, -P(0)(R)-, -P(0)( R 2 )-, -S- C(0)0- -C(O)-, -S(O)-, -S(0) 2 - - N(R)S(0) 2 - -S(0) 2 N(R)-, -N - : OC(0)N(R)-, N(R)C(0)0-
  • L is selected from those depicted in Table 1, below.
  • n 0, 1, or 2.
  • m is 0. In some embodiments, m is 1. In some embodiments, m is 2.
  • m is selected from those depicted in Table 1, below.
  • n 0, 1, 2, 3, or 4.
  • n is 0. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4.
  • n is selected from those depicted in Table 1, below.
  • p is 0. In some embodiments, p is 1. In some embodiments, p
  • p is selected from those depicted in Table 1, below.
  • each of q is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • q is 0. In some embodiments, q is 1. In some embodiments, q is 2. In some embodiments, q is 3. In some embodiments, q is 4. In some embodiments, q is 5. In some embodiments, q is 6. In some embodiments, q is 7. In some embodiments, q is 8. In some embodiments, q is 9. In some embodiments, q is 10.
  • the TBM group is a group, which binds to target proteins.
  • Targets of the TBM group are numerous in kind and are selected from proteins that are expressed in a cell such that at least a portion of the sequences is found in the cell and may bind to a TBM group.
  • the term"protein” includes oligopeptides and polypeptide sequences of sufficient length that they can bind to a TBM group according to the present invention. Any protein in a eukaryotic system, as described herein, are targets for ubiquitination mediated by the compounds according to the present invention.
  • TBM groups according to the present invention include, for example, include any moiety which binds to a protein specifically (binds to a target protein) and includes the following non-limiting examples of small molecule target protein moieties: Hsp90 inhibitors, kinase inhibitors, HDM2 & MDM2 inhibitors, compounds targeting Human BET Bromodomain- containing proteins, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, nuclear hormone receptor compounds, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR), among numerous others.
  • the compositions described below exemplify some of the members of these nine types of small molecule target protein binding moieties.
  • Such small molecule target protein binding moieties also include pharmaceutically acceptable salts, enantiomers, solvates and polymorphs of these compositions, as well as other small molecules that may target a protein of interest.
  • These binding moieties are linked to the ubiquitin ligase binding moiety preferably through a linker in order to present a target protein (to which the protein target moiety is bound) in proximity to the ubiquitin ligase for ubiquitination and degradation.
  • target proteins may include, for example, structural proteins, receptors, enzymes, cell surface proteins, proteins pertinent to the integrated function of a cell, including proteins involved in catalytic activity, aromatase activity, motor activity, helicase activity, metabolic processes (anabolism and catabolism), antioxidant activity, proteolysis, biosynthesis, proteins with kinase activity, oxidoreductase activity, transferase activity, hydrolase activity, lyase activity, isomerase activity, ligase activity, enzyme regulator activity, signal transducer activity, structural molecule activity, binding activity (protein, lipid carbohydrate), receptor activity, cell motility, membrane fusion, cell communication, regulation of biological processes, development, cell differentiation, response to stimulus, behavioral proteins, cell adhesion proteins, proteins involved in cell death, proteins involved in transport (including protein transport
  • Proteins of interest can include proteins from eurkaryotes and prokaryotes including humans as targets for drug therapy, other animals, including domesticated animals, microbials for the determination of targets for antibiotics and other antimicrobials and plants, and even viruses, among numerous others.
  • TBM (or target binding moiety) is a small molecule which is capable of binding to or binds to a target protein of interest.
  • TBMs which include but are not limited to Hsp90 inhibitors, kinase inhibitors, MDM2 inhibitors, compounds targeting Human BET Bromodomain-containing proteins, compounds targeting cytosolic signaling protein FKBP12, HDAC inhibitors, human lysine methyltransferase inhibitors, angiogenesis inhibitors, immunosuppressive compounds, and compounds targeting the aryl hydrocarbon receptor (AHR).
  • TBM is a BRD ligand selected from
  • TBM is a glucocorticoid receptor ligand selected from
  • TBM is a RasG12C ligand selected from
  • TBM is a Bcl-2/Bcl-XL ligand selected from
  • TBM is an Abl, KRAS, SHP2, cRAF, MerTK or PRMT5 ligand that are selected from the following non-limiting examples:
  • a TBM moiety is selected from PTM moieties as recited in WO 2016/197032 the entirety of which is incorporated herein by reference. In some embodiments, a TBM moiety is selected from such inhibitors as described in WO 2016/197032 at paragraphs [00116] through [00173] wherein the recitation of a "Linker" moiety in WO 2016/197032 corresponds to the -L- group as defined and described herein.
  • the method employs a compound set forth in Table 1, above, or a pharmaceutically acceptable salt thereof.
  • the present invention provides a compound of formula I, wherein the compound is not any of compounds depicted in Table A-1, below.
  • the present invention provides a compound of formula II-A, wherein the compound is not any of compounds depicted in Table A-2, below.
  • ADX10059 antimigraine agent for treatment of GRM5 gastroesophageal reflux disease
  • succinobucol antiatherosclerosis agent VCAM1 succinobucol antiatherosclerosis agent
  • AGN-214868 analgesic,neuralgia ADRA1A
  • AGN-214868 analgesic,neuralgia ADRA1B
  • AGN-214868 analgesic,neuralgia ADRA1D
  • AGN-214868 analgesic,neuralgia ADRA2A
  • AGN-214868 analgesic,neuralgia ADRA2B
  • AGN-214868 analgesic,neuralgia ADRA2C Drug Name Indication(s) Gene agomelatine antidepressant MTNR1B agomelatine antidepressant HTR2B agomelatine antidepressant HTR2C agomelatine antidepressant MTNR1A hydroxychloroquine antirheumatic agent TLR7 hydroxychloroquine antirheumatic agent TLR9 paclitaxel antineoplastic agent BCL2 paclitaxel antineoplastic agent TUBB1
  • buprenorphine antidepressant for OPRD1 treatment of opioid addiction
  • buprenorphine antidepressant for OPRK1 treatment of opioid addiction
  • altropane diagnostic agent for parkinson's SLC6A3 disease and ADHD
  • ADRB3 amifostine radiation-protective agent ALPPL2 amiodarone antiarrhytmic agent ADRA1A amiodarone antiarrhytmic agent ADRB1 amiodarone antiarrhytmic agent KC H2 amisulpride antipsychotic agent DRD2 amisulpride antipsychotic agent DRD3 amitriptyline analgesic SLC6A2 amitriptyline analgesic SLC6A4 ketamine analgesic GRIN3A amlodipine antihypertensive agent, CACNA1C cardiovascular agent
  • amlodipine antihypertensive agent CACNA1D cardiovascular agent Drug Name Indication(s) Gene amlodipine antihypertensive agent, CACNA1 S cardiovascular agent
  • amlodipine antihypertensive agent CACNA2D1 cardiovascular agent
  • amlodipine antihypertensive agent CACNB2 cardiovascular agent
  • Anacetrapib for treatment of dyslipidemia CETP anamorelin appetite stimulating agent GHSR anastrozole antineoplastic agent CYP19A1 anatibant for treatment of traumatic brain BDKRB2 injury
  • ARRY-614 for treatment of myelodysplastic ABLl syndrome
  • ARRY-614 for treatment of myelodysplastic KDR syndrome
  • ARRY-614 for treatment of myelodysplastic MAPK11 syndrome Drug Name Indication(s) Gene
  • ARRY-614 for treatment of myelodysplastic MAPK12 syndrome
  • ARRY-614 for treatment of myelodysplastic MAPK13 syndrome
  • ARRY-614 for treatment of myelodysplastic MAPK14 syndrome
  • arverapamil for treatment of irritable bowel CACNA1 S syndrome Drug Name Indication(s) Gene arverapamil for treatment of irritable bowel CAC B1 syndrome
  • Arzoxifene antineoplastic agent antiosteoporotic ESR1 agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PCT/US2018/052242 2017-09-22 2018-09-21 AGENTS FOR DEGRADING PROTEINS AND USES THEREOF Ceased WO2019060742A1 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
EP18857581.5A EP3684365A4 (en) 2017-09-22 2018-09-21 PROTEIN DEGRADATION AGENTS AND USES OF SUCH
IL273432A IL273432B (en) 2017-09-22 2018-09-21 Protein compounds and their uses
IL307995A IL307995A (en) 2017-09-22 2018-09-21 Protein compounds and their uses
EP25195747.8A EP4624467A3 (en) 2017-09-22 2018-09-21 Protein degraders and uses thereof
AU2018338314A AU2018338314B2 (en) 2017-09-22 2018-09-21 Protein degraders and uses thereof
US16/649,732 US11623932B2 (en) 2017-09-22 2018-09-21 Protein degraders and uses thereof
CA3076613A CA3076613A1 (en) 2017-09-22 2018-09-21 Protein degraders and uses thereof
JP2020538753A JP7366031B2 (ja) 2017-09-22 2018-09-21 タンパク質分解剤およびそれらの使用
MX2020003190A MX2020003190A (es) 2017-09-22 2018-09-21 Degradadores de proteinas y usos de los mismos.
IL295603A IL295603B2 (en) 2017-09-22 2018-09-21 Protein degraders and uses thereof
IL322809A IL322809A (en) 2017-09-22 2018-09-21 Protein Decomposers and Their Uses
US17/837,449 US20230115184A1 (en) 2017-09-22 2022-06-10 Protein degraders and uses thereof
JP2023175302A JP7818560B2 (ja) 2017-09-22 2023-10-10 タンパク質分解剤およびそれらの使用
AU2025201796A AU2025201796A1 (en) 2017-09-22 2025-03-12 Protein degraders and uses thereof
US19/304,052 US20260085075A1 (en) 2017-09-22 2025-08-19 Protein degraders and uses thereof
JP2025136973A JP2025170324A (ja) 2017-09-22 2025-08-20 タンパク質分解剤およびそれらの使用

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762562206P 2017-09-22 2017-09-22
US62/562,206 2017-09-22
US201762610403P 2017-12-26 2017-12-26
US62/610,403 2017-12-26
US201862714527P 2018-08-03 2018-08-03
US62/714,527 2018-08-03

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US16/649,732 A-371-Of-International US11623932B2 (en) 2017-09-22 2018-09-21 Protein degraders and uses thereof
US17/837,449 Continuation US20230115184A1 (en) 2017-09-22 2022-06-10 Protein degraders and uses thereof

Publications (1)

Publication Number Publication Date
WO2019060742A1 true WO2019060742A1 (en) 2019-03-28

Family

ID=65810510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2018/052242 Ceased WO2019060742A1 (en) 2017-09-22 2018-09-21 AGENTS FOR DEGRADING PROTEINS AND USES THEREOF

Country Status (8)

Country Link
US (3) US11623932B2 (https=)
EP (2) EP4624467A3 (https=)
JP (3) JP7366031B2 (https=)
AU (2) AU2018338314B2 (https=)
CA (2) CA3283159A1 (https=)
IL (4) IL273432B (https=)
MX (3) MX2020003190A (https=)
WO (1) WO2019060742A1 (https=)

Cited By (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110596403A (zh) * 2019-09-17 2019-12-20 中山大学附属第一医院 用于卵巢癌诊断的特异性蛋白标记物及制备方法
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
CN110749733A (zh) * 2019-12-06 2020-02-04 四川大学华西医院 Tgif2ly自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
CN111214664A (zh) * 2020-02-24 2020-06-02 大连医科大学 USP2和HSP90抑制剂联合使用抑制ErbB2阳性乳腺癌生长的应用
WO2020206424A1 (en) * 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Stat degraders and uses thereof
WO2020215844A1 (zh) * 2019-04-25 2020-10-29 中国科学院化学研究所 用于筛选lrpprc调控剂的产品及鉴定lrpprc调控剂的方法
JP2020183905A (ja) * 2019-05-08 2020-11-12 国立大学法人高知大学 認知症治療薬のスクリーニング方法
WO2020236901A1 (en) * 2019-05-20 2020-11-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education A novel therapy for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp)
US10874743B2 (en) 2017-12-26 2020-12-29 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2021041942A1 (en) * 2019-08-28 2021-03-04 University Of Kentucky Research Foundation Collagen p4h1 inhibitor and its use
CN112899351A (zh) * 2021-02-03 2021-06-04 东华大学 一种双重荧光定量pcr检测pdx模型小鼠细胞浸润状态试剂盒
WO2021127586A1 (en) * 2019-12-20 2021-06-24 Calico Life Sciences Llc Protein tyrosine phosphatase degraders and methods of use thereof
WO2021127561A1 (en) 2019-12-20 2021-06-24 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
CN113186273A (zh) * 2021-05-13 2021-07-30 中国人民解放军总医院第一医学中心 一种用于预测P2Y12受体拮抗剂抗血小板疗效的circRNA检测试剂盒及其应用
WO2021162493A1 (ko) * 2020-02-14 2021-08-19 보로노이 주식회사 단백질 키나아제 분해 유도 화합물 및 이의 용도
US11117889B1 (en) 2018-11-30 2021-09-14 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP3878847A1 (en) * 2020-03-13 2021-09-15 Centre Régional de Lutte contre le Cancer - Centre François Baclesse Bcl-2 family proteins modulating compounds for cancer treatment
WO2021188696A1 (en) * 2020-03-17 2021-09-23 Kymera Therapeutics, Inc. Stat degraders and uses thereof
WO2021236885A1 (en) * 2020-05-21 2021-11-25 Dana-Farber Cancer Institute, Inc. Piperidine-2,6-diones as small molecule degraders of helios and methods of use
CN113817833A (zh) * 2021-10-26 2021-12-21 常州国药医学检验实验室有限公司 一种基于荧光定量pcr技术的检测宫颈细胞基因甲基化的试剂盒与应用
CN113817818A (zh) * 2021-10-22 2021-12-21 常州市第二人民医院 用于诊断过敏性气道炎症的工具
KR20220006012A (ko) * 2020-07-07 2022-01-14 한국식품연구원 Cmip 억제제를 포함하는 지방간 질환의 예방 또는 치료용 약학적 조성물
WO2022012623A1 (en) * 2020-07-16 2022-01-20 Beigene, Ltd. Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
JP2022025029A (ja) * 2020-07-17 2022-02-09 国立医薬品食品衛生研究所長 新規化合物及び医薬組成物
EP3953332A1 (en) 2019-04-12 2022-02-16 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
WO2022077010A1 (en) * 2020-10-07 2022-04-14 Kymera Therapeutic, Inc. Stat degraders and uses thereof
WO2022109426A1 (en) * 2020-11-20 2022-05-27 Foghorn Therapeutics Inc. Compounds and uses thereof
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
CN114656509A (zh) * 2022-04-08 2022-06-24 国科温州研究院(温州生物材料与工程研究所) 一种氮杂环卡宾-金钯合金纳米粒子及其制备方法和应用
US11459335B2 (en) 2017-06-20 2022-10-04 C4 Therapeutics, Inc. N/O-linked Degrons and Degronimers for protein degradation
WO2022216675A1 (en) * 2021-04-06 2022-10-13 Believe In A Cure, Inc. [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)- amino]-acetic acid for use in increasing foxg1 expression
US11471455B2 (en) 2018-10-05 2022-10-18 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
CN115380026A (zh) * 2020-03-17 2022-11-22 南京明德新药研发有限公司 蛋白降解调节剂与其使用方法
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11524949B2 (en) 2017-11-16 2022-12-13 C4 Therapeutics, Inc. Degraders and Degrons for targeted protein degradation
WO2022271727A1 (en) * 2021-06-21 2022-12-29 Calico Life Sciences Llc Degrader compounds and uses thereof
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
CN115639306A (zh) * 2022-12-26 2023-01-24 四川大学华西医院 一种快速检测临床样本中抗癫痫药物浓度的方法
JP2023507172A (ja) * 2019-12-17 2023-02-21 オリオニス バイオサイエンシズ，インコーポレイテッド タンパク質分解の調節
US11584748B2 (en) 2018-04-16 2023-02-21 C4 Therapeutics, Inc. Spirocyclic compounds
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
WO2023107706A1 (en) * 2021-12-11 2023-06-15 Kymera Therapeutics, Inc. Stat3 degraders and uses thereof
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
KR20230091051A (ko) * 2021-12-14 2023-06-22 (주)프레이저테라퓨틱스 폴리유비퀴틴화에 의한 표적 단백질 또는 폴리펩티드의 분해용 신규 화합물
US11685750B2 (en) 2020-06-03 2023-06-27 Kymera Therapeutics, Inc. Crystalline forms of IRAK degraders
US11691972B2 (en) 2020-03-05 2023-07-04 C4 Therapeutics, Inc. Compounds for targeted degradation of BRD9
US11707457B2 (en) 2019-12-17 2023-07-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11753397B2 (en) 2018-03-26 2023-09-12 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
CN116813608A (zh) * 2023-06-08 2023-09-29 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
WO2023232133A1 (zh) 2022-06-02 2023-12-07 西藏海思科制药有限公司 一种抑制或降解Bcl6的化合物及其在医药中的应用
WO2023225647A3 (en) * 2022-05-19 2023-12-28 University Of Puerto Rico Novel targets against ovarian cancer
WO2023250058A1 (en) * 2022-06-22 2023-12-28 Kymera Therapeutics, Inc. Stat degraders and uses thereof
WO2024006776A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
WO2024006781A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and use thereof
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
US11932624B2 (en) 2020-03-19 2024-03-19 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
WO2024075696A1 (ja) 2022-10-03 2024-04-11 公立大学法人横浜市立大学 二環性構造を有するイミダゾピリジン誘導体
US11958837B2 (en) 2017-12-21 2024-04-16 Ribon Therapeutics, Inc. Quinazolinones as PARP14 inhibitors
US11986532B2 (en) 2021-04-16 2024-05-21 Arvinas Operations, Inc. Modulators of BCL6 proteolysis and associated methods of use
WO2024157953A1 (ja) 2023-01-24 2024-08-02 第一三共株式会社 置換ベンゼン化合物
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
US12150995B2 (en) 2020-12-30 2024-11-26 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
WO2025006783A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras
US12187744B2 (en) 2021-10-29 2025-01-07 Kymera Therapeutics, Inc. IRAK4 degraders and synthesis thereof
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
US20250144225A1 (en) * 2023-10-03 2025-05-08 PAQ Therapeutics Inc. KRAS Proteolysis Targeting Chimeras
US12310975B2 (en) 2019-10-17 2025-05-27 Arvinas Operations, Inc. Modulators of BCL6 proteolysis and associated methods of use
JP2025113407A (ja) * 2019-06-28 2025-08-01 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびその使用
WO2025194014A1 (en) 2024-03-15 2025-09-18 Dem Biopharma, Inc. Hetero aryl modulators of apmap and uses thereof
US12421220B2 (en) 2022-06-06 2025-09-23 C4 Therapeutics, Inc. Bicyclic-substituted glutarimide cereblon binders
AU2020295399B2 (en) * 2019-06-18 2025-10-16 Dana-Farber Cancer Institute, Inc. Small molecule target bromo/acetyl proteins and uses thereof
CN120794955A (zh) * 2025-07-07 2025-10-17 四川伊诺唯新生物医药有限公司 一种irak4靶向蛋白降解剂关键中间体的制备方法
US12454521B2 (en) 2018-12-20 2025-10-28 C4 Therapeutics, Inc. Targeted protein degradation
US12486253B2 (en) 2021-06-08 2025-12-02 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant BRAF
US12497402B2 (en) 2021-02-15 2025-12-16 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
US12516068B2 (en) 2018-01-12 2026-01-06 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US12521438B2 (en) 2019-06-10 2026-01-13 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12559492B2 (en) 2020-06-19 2026-02-24 C4 Therapeutics, Inc. BRAF degraders
US12565492B2 (en) 2024-08-09 2026-03-03 Triana Biomedicines, Inc. Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US12606533B2 (en) 2023-09-29 2026-04-21 Daiichi Sankyo Company, Limited 3-phenylpropylamine derivative

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102674902B1 (ko) 2016-12-01 2024-06-14 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
AU2018211975B2 (en) 2017-01-26 2022-05-26 Arvinas Operations, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
US12539292B2 (en) 2018-04-01 2026-02-03 Arvinas Operations, Inc. BRM targeting compounds and associated methods of use
KR20210006356A (ko) 2018-04-04 2021-01-18 아비나스 오퍼레이션스, 인코포레이티드 단백질분해 조절제 및 연관된 사용 방법
IL320609A (en) 2019-08-26 2025-07-01 Arvinas Operations Inc Methods for treating breast cancer with a history of tetrahydronaphthalene as estrogen receptor-disrupting agents
KR20230004511A (ko) 2020-03-21 2023-01-06 아비나스 오퍼레이션스, 인코포레이티드 인다졸계 화합물 및 관련된 사용 방법
WO2022198112A1 (en) 2021-03-19 2022-09-22 Arvinas Operations, Inc. Indazole based compounds and associated methods of use
AU2022292649A1 (en) * 2021-06-16 2024-01-04 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
CN113637750A (zh) * 2021-07-16 2021-11-12 宁波市第一医院 急性髓系白血病的辅助诊断、预后诊断或危险度分层标记物及其应用
CA3265344A1 (en) * 2022-08-19 2024-02-22 University Of Louisiana Monroe METHOD FOR THE DIAGNOSTIC AND TREATMENT OF PROSTATE CANCER USING ZINC FINGER-PATTERNED PROTEIN TYPE 1 ANTIBODIES
CN121419983A (zh) 2023-01-26 2026-01-27 阿尔维纳斯运营股份有限公司 基于小脑蛋白的kras降解protac及其相关用途
WO2024173718A2 (en) * 2023-02-16 2024-08-22 St. Jude Children's Research Hospital Heterobifunctional binders of klhdc2
CN117205322A (zh) * 2023-09-08 2023-12-12 河南大学 Fer1l6基因在糖尿病防治中的应用
AU2024352092A1 (en) 2023-09-28 2026-04-09 Arvinas Operations, Inc. Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (lrrk2)
WO2025096984A1 (en) * 2023-11-02 2025-05-08 The Regents Of The University Of California Gtpase inhibitors and uses thereof
CN117756818B (zh) * 2023-12-12 2025-04-29 北京医院 一种戊二酰亚胺类化合物及其制备方法和应用
CN118702679B (zh) * 2024-08-26 2024-10-29 四川大学华西医院 一种具有ezh2/brd4双靶点活性的化合物、药物组合物及其制备方法和用途
CN120330336A (zh) * 2025-03-19 2025-07-18 中南大学湘雅医院 一种用于宫颈癌和/或宫颈癌前病变检测的甲基化标志物组合及其应用、产品、检测装置、计算机可读存储介质、电子终端和计算机程序

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160058872A1 (en) * 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation

Family Cites Families (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650270A (en) 1982-02-01 1997-07-22 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5516931A (en) 1982-02-01 1996-05-14 Northeastern University Release tag compounds producing ketone signal groups
US4650750A (en) 1982-02-01 1987-03-17 Giese Roger W Method of chemical analysis employing molecular release tag compounds
US4709016A (en) 1982-02-01 1987-11-24 Northeastern University Molecular analytical release tags and their use in chemical analysis
US5360811A (en) 1990-03-13 1994-11-01 Hoechst-Roussel Pharmaceuticals Incorporated 1-alkyl-, 1-alkenyl-, and 1-alkynylaryl-2-amino-1,3-propanediols and related compounds as anti-inflammatory agents
JP3545461B2 (ja) 1993-09-10 2004-07-21 エーザイ株式会社 二環式ヘテロ環含有スルホンアミド誘導体
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
US6306663B1 (en) 1999-02-12 2001-10-23 Proteinex, Inc. Controlling protein levels in eucaryotic organisms
EP1382339B1 (en) 1999-12-10 2007-12-05 Pfizer Products Inc. Compositions containing pyrrolo ¬2,3-d pyrimidine derivatives
DE10002509A1 (de) 2000-01-21 2001-07-26 Gruenenthal Gmbh Substituierte Glutarimide
ES2243461T3 (es) 2000-02-28 2005-12-01 Sugen, Inc. Compuestos de 3-(pirolillactona) -2-indolinona como inhibidores quinasa.
PE20020354A1 (es) 2000-09-01 2002-06-12 Novartis Ag Compuestos de hidroxamato como inhibidores de histona-desacetilasa (hda)
US7208157B2 (en) 2000-09-08 2007-04-24 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
US7041298B2 (en) 2000-09-08 2006-05-09 California Institute Of Technology Proteolysis targeting chimeric pharmaceutical
EP1389617B1 (en) 2001-04-27 2007-01-03 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compound and antitumor agent containing the same as active ingredient
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
WO2004019973A1 (en) 2002-08-14 2004-03-11 Atugen Ag Use of protein kinase n beta
KR20070087266A (ko) 2003-04-03 2007-08-28 세마포르 파머슈티컬즈, 아이엔씨. 피아이-3 키나아제 억제제 프로드러그
CN1832939B (zh) 2003-05-30 2010-04-28 杰明X医药品加拿大公司 用于治疗癌症或病毒病的三杂环化合物、组合物和方法
US7173015B2 (en) 2003-07-03 2007-02-06 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
JP4398263B2 (ja) 2004-01-13 2010-01-13 富士通株式会社 経路設計方法
SI2612862T1 (sl) 2004-05-13 2017-04-26 Icos Corporation Kinazolini kot inhibitorji humane fosfatidilinozitol 3-kinaze delta
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
DE602006010979D1 (de) 2005-01-19 2010-01-21 Rigel Pharmaceuticals Inc Prodrugs aus 2,4-pyrimidindiamin-verbindungen und ihre verwendungen
AU2006230099B2 (en) 2005-03-25 2012-04-19 Gitr, Inc. GITR binding molecules and uses therefor
EP1888550B1 (en) 2005-05-12 2014-06-25 AbbVie Bahamas Ltd. Apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
BRPI0617162B8 (pt) 2005-10-07 2021-05-25 Exelixis Inc compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos
CN103626742B (zh) 2005-11-01 2017-04-26 塔格根公司 激酶的联-芳基间-嘧啶抑制剂
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
UA96283C2 (uk) 2005-12-23 2011-10-25 Зіланд Фарма А/С Модифіковані міметики лізину
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
MX2008013578A (es) 2006-04-26 2009-03-23 Hoffmann La Roche Derivados de tieno [3,2-d]pirimidina utiles como inhibidores de fosfatidilinositol 3-cinasa(p13k).
BRPI0622054B8 (pt) 2006-09-22 2021-05-25 Oxford Amherst Llc composto e composição farmacêutica
US20100279316A1 (en) 2007-01-19 2010-11-04 Leonid Gorelik Antibodies to Phosphorylated IRAK4
HRP20151386T1 (hr) 2007-03-12 2016-02-26 Ym Biosciences Australia Pty Ltd Fenil aminopirimidinski spojevi i njihova primjena
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
ES2776406T3 (es) 2007-07-12 2020-07-30 Gitr Inc Terapias de combinación que emplean moléculas de enlazamiento a GITR
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
EP2217716A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS
JP5583592B2 (ja) 2007-11-30 2014-09-03 ニューリンク ジェネティクス コーポレイション Ｉｄｏ阻害剤
US8158616B2 (en) 2008-03-11 2012-04-17 Incyte Corporation Azetidine and cyclobutane derivatives as JAK inhibitors
JP2011518841A (ja) 2008-04-24 2011-06-30 ニューリンク ジェネティクス， インコーポレイテッド Ｉｄｏ阻害剤
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
AU2009333580B2 (en) 2008-12-09 2016-07-07 Genentech, Inc. Anti-PD-L1 antibodies and their use to enhance T-cell function
US8921037B2 (en) 2008-12-16 2014-12-30 Bo Han PF4-depleted platelet rich plasma preparations and methods for hard and soft tissue repair
EP2473531A4 (en) 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr antibodies
JP2012254939A (ja) 2009-10-07 2012-12-27 Astellas Pharma Inc オキサゾール化合物
US8722720B2 (en) 2009-10-28 2014-05-13 Newlink Genetics Corporation Imidazole derivatives as IDO inhibitors
PH12012500881A1 (en) 2009-12-10 2017-07-26 Hoffmann La Roche Antibodies binding preferentially human csf1r extracellular domain 4 and their use
JP5998060B2 (ja) 2010-03-04 2016-09-28 マクロジェニクス，インコーポレーテッド Ｂ７−ｈ３と反応性のある抗体、その免疫学的に活性なフラグメントおよびその使用
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
CA2789076C (en) 2010-03-05 2017-11-21 F. Hoffmann-La Roche Ag Antibodies against human colony stimulating factor-1 receptor and uses thereof
US8114621B2 (en) 2010-03-12 2012-02-14 Saladax Biomedical Inc. Lenalidomide and thalidomide immunoassays
MX378336B (es) 2010-05-04 2025-03-10 Five Prime Therapeutics Inc Anticuerpos que se unen a factor estimulante de colonias 1 (csf1r).
SG186389A1 (en) 2010-06-30 2013-01-30 Univ Brandeis Small-molecule-targeted protein degradation
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
PT2614082T (pt) 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
KR20180099933A (ko) 2010-11-19 2018-09-05 리간드 파마슈티칼스 인코포레이티드 복소환 아민 및 이의 용도
AU2011338615B2 (en) 2010-12-07 2017-07-27 Yale University Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
BR112013015460B1 (pt) 2010-12-20 2022-01-25 Merck Serono S.A. Derivados de indazolil triazol, kit, e composição farmacêutica
US8703941B2 (en) 2011-01-10 2014-04-22 Nimbus Iris, Inc. IRAK inhibitors and uses thereof
WO2012129258A1 (en) 2011-03-22 2012-09-27 Merck Sharp & Dohme Corp. Amidopyrazole inhibitors of interleukin receptor-associated kinases
NO2694640T3 (https=) 2011-04-15 2018-03-17
KR101970025B1 (ko) 2011-04-20 2019-04-17 메디뮨 엘엘씨 Ｂ7-ｈ1 및 ｐｄ-1과 결합하는 항체 및 다른 분자들
WO2013042137A1 (en) 2011-09-19 2013-03-28 Aurigene Discovery Technologies Limited Bicyclic heterocycles as irak4 inhibitors
WO2013066729A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Aminopyrimidinones as interleukin receptor-associated kinase inhibitors
HRP20201595T1 (hr) 2011-11-28 2020-12-11 Merck Patent Gmbh Anti-pd-l1 protutijela i njihova uporaba
BR112014012624A2 (pt) 2011-12-15 2018-10-09 F Hoffmann-La Roche Ag anticorpos, composição farmacêutica, ácido nucleico, vetores de expressão, célula hospedeira, método para a produção de um anticorpo recombinante e uso do anticorpo
CN104582705A (zh) 2012-01-10 2015-04-29 林伯士艾瑞斯公司 白介素-1受体相关激酶(irak)抑制剂和其用途
WO2013106646A2 (en) 2012-01-12 2013-07-18 Yale University Compounds and methods for the inhibition of vcb e3 ubiquitin ligase
CA2861066C (en) 2012-01-12 2024-01-02 Yale University Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an e3 ubiquitin ligase
CN104254533B (zh) 2012-01-13 2017-09-08 百时美施贵宝公司 用作激酶抑制剂的噻唑或噻二唑取代的吡啶基化合物
WO2013106614A1 (en) 2012-01-13 2013-07-18 Bristol-Myers Squibb Company Triazolyl-substituted pyridyl compounds useful as kinase inhibitors
EP2802576B1 (en) 2012-01-13 2018-06-27 Bristol-Myers Squibb Company Heterocyclic-substituted pyridyl compounds useful as kinase inhibitors
RU2014136332A (ru) 2012-02-06 2016-03-27 Дженентек, Инк. Композиции и способы применения ингибиторов csf1r
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
EP2847220A1 (en) 2012-05-11 2015-03-18 Five Prime Therapeutics, Inc. Methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (csf1r)
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
SG11201500005SA (en) 2012-07-10 2015-01-29 Ares Trading Sa Pyrimidine pyrazolyl derivatives
US20140018361A1 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2014011906A2 (en) 2012-07-11 2014-01-16 Nimbus Iris, Inc. Irak inhibitors and uses thereof
HK1210696A1 (en) 2012-07-11 2016-05-06 Nimbus Iris, Inc. Irak inhibitors and uses thereof
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US9422331B2 (en) 2012-09-19 2016-08-23 Hoffmann-La Roche Inc. 2-oxo-2,3,4,5-tetrahydro-1 H-benzo[B]diazepines and their use in the treatment of cancer
WO2014058691A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
WO2014058685A1 (en) 2012-10-08 2014-04-17 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
KR20150079963A (ko) 2012-11-08 2015-07-08 브리스톨-마이어스 스큅 컴퍼니 키나제 조절제로서 유용한 헤테로아릴 치환된 피리딜 화합물
GB201311910D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel Compounds
EP2953944B1 (en) 2013-02-07 2017-04-26 Merck Patent GmbH Pyridazinone-amides derivatives
LT2953952T (lt) 2013-02-07 2017-08-25 Merck Patent Gmbh Makrocikliniai piridazinono dariniai
EP2970334B1 (en) 2013-03-15 2018-05-23 Biogen MA Inc. Macrocyclic compounds as irak4 inhibitors for the treatment of inflammatory diseases
BR112016006319A2 (pt) 2013-09-27 2017-08-01 Nimbus Iris Inc inibidores de irak e usos dos mesmos
CN105899505B (zh) 2013-11-08 2018-08-28 武田药品工业株式会社 用于治疗自身免疫病症的吡唑
JP6680683B2 (ja) 2013-11-18 2020-04-15 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト テトラヒドロ−ベンゾジアゼピノン類
JP6496731B2 (ja) 2013-11-27 2019-04-03 シグナルケム・ライフサイエンシーズ・コーポレイションＳｉｇｎａｌｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ Ｔａｍファミリーキナーゼ阻害剤としてのアミノピリジン誘導体
TWI667233B (zh) 2013-12-19 2019-08-01 德商拜耳製藥公司 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途
TW201609693A (zh) 2014-01-03 2016-03-16 必治妥美雅史谷比公司 雜芳基取代之菸鹼醯胺化合物
SG11201605408RA (en) 2014-01-10 2016-07-28 Aurigene Discovery Tech Ltd Indazole compounds as irak4 inhibitors
FI3805233T3 (fi) 2014-01-13 2024-04-17 Aurigene Oncology Ltd N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon
RU2016137674A (ru) 2014-03-17 2018-04-18 Ф. Хоффманн-Ля Рош Аг Производные пиперидиндиона
MA39838B1 (fr) 2014-04-04 2019-05-31 Pfizer Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
AU2015247817C1 (en) 2014-04-14 2022-02-10 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
JP2017513954A (ja) 2014-04-22 2017-06-01 ニンバス アイリス， インコーポレイテッド Ｉｒａｋ阻害剤およびその使用
JP2017518348A (ja) 2014-06-20 2017-07-06 オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ Ｉｒａｋ４阻害剤としての置換インダゾール化合物
WO2015200795A1 (en) 2014-06-27 2015-12-30 Celgene Corporation Compositions and methods for inducing conformational changes in cereblon other e3 ubiquitin ligases
US10246456B2 (en) 2014-07-18 2019-04-02 Biogen Ma Inc. IRAK4 inhibiting agents
US20160022642A1 (en) 2014-07-25 2016-01-28 Yale University Compounds Useful for Promoting Protein Degradation and Methods Using Same
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
EP3200790B1 (en) 2014-09-30 2020-08-26 Merck Sharp & Dohme Corp. Inhibitors of irak4 activity
US9969749B2 (en) 2014-09-30 2018-05-15 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
US9926330B2 (en) 2014-09-30 2018-03-27 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
US9932350B2 (en) 2014-09-30 2018-04-03 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
CA2964982C (en) 2014-11-20 2022-07-05 Merck Patent Gmbh Heteroaryl compounds as irak inhibitors and uses thereof
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
JP6815318B2 (ja) * 2014-12-23 2021-01-20 ダナ−ファーバー キャンサー インスティテュート，インコーポレイテッド 二官能性分子によって標的化タンパク質分解を誘導する方法
US12312316B2 (en) 2015-01-20 2025-05-27 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
JP6817962B2 (ja) 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． ターゲティングされたアンドロゲン受容体分解のための化合物および方法
WO2016144848A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrrolotriazine inhibitors of irak4 activity
EP3268003B1 (en) 2015-03-12 2020-07-29 Merck Sharp & Dohme Corp. Thienopyrazine inhibitors of irak4 activity
US10040798B2 (en) 2015-03-12 2018-08-07 Merck Sharp & Dohme Corp. Pyrrolopyridazine inhibitors of IRAK4 activity
EP3267996B1 (en) 2015-03-12 2020-11-11 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
US10155765B2 (en) 2015-03-12 2018-12-18 Merck Sharp & Dohme Corp. Carboxamide inhibitors of IRAK4 activity
US10730870B2 (en) 2015-03-18 2020-08-04 Arvinas Operations, Inc. Compounds and methods for the enhanced degradation of targeted proteins
EA039043B1 (ru) 2015-04-22 2021-11-25 Райджел Фармасьютикалз, Инк. Пиразольные соединения и способ получения и применения данных соединений
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
UY36660A (es) 2015-04-30 2016-11-30 Bayer Pharma AG Combinaciones de inhibidores de irak4
HUE054149T2 (hu) * 2015-06-04 2021-08-30 Arvinas Operations Inc Proteolízis imid-alapú modulátorai és ezekkel kapcsolatos felhasználási eljárások
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
TW201718571A (zh) 2015-06-24 2017-06-01 必治妥美雅史谷比公司 經雜芳基取代之胺基吡啶化合物
CN105085620B (zh) 2015-06-25 2018-05-08 中山大学附属第一医院 一种靶向泛素化降解Smad3的化合物
WO2017004134A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017004133A1 (en) 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017011371A1 (en) 2015-07-10 2017-01-19 Arvinas, Inc Mdm2-based modulators of proteolysis and associated methods of use
CA2988436A1 (en) 2015-07-13 2017-01-19 Arvinas, Inc. Alanine-based modulators of proteolysis and associated methods of use
BR112018000624A2 (pt) 2015-07-15 2018-09-18 Aurigene Discovery Technologies Limited compostos de indazol e azaindazol como inibidores de irak-4
JP2018524365A (ja) 2015-07-15 2018-08-30 アウリジーン ディスカバリー テクノロジーズ リミテッド Ｉｒａｋ−４阻害剤としての置換アザ化合物
EP3337476A4 (en) 2015-08-19 2019-09-04 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
ES2865199T3 (es) 2015-08-27 2021-10-15 Pfizer Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4
KR102650026B1 (ko) 2015-09-18 2024-03-22 메르크 파텐트 게엠베하 Irak 억제제로서의 헤테로아릴 화합물 및 이의 용도
CN108290879B (zh) 2015-09-18 2022-01-11 默克专利有限公司 用作irak抑制剂的杂芳基化合物及其用途
WO2017059280A1 (en) 2015-10-02 2017-04-06 The University Of North Carolina At Chapel Hill Novel pan-tam inhibitors and mer/axl dual inhibitors
AU2016349781A1 (en) 2015-11-02 2018-05-10 Yale University Proteolysis targeting chimera compounds and methods of preparing and using same
EP3394066A2 (en) 2015-12-22 2018-10-31 H. Hoffnabb-La Roche Ag PYRAZOLO[1,5a]PYRIMIDINE DERIVATIVES AS IRAK4 MODULATORS
US20200216454A1 (en) 2015-12-30 2020-07-09 Dana-Farber Cancer Institute, Inc. Bifunctional molecules for her3 degradation and methods of use
US20190016703A1 (en) 2015-12-30 2019-01-17 Dana-Farber Cancer Institute, Inc. Bifunctional compounds for her3 degradation and methods of use
WO2017127430A1 (en) 2016-01-20 2017-07-27 Biogen Ma Inc. Irak4 inhibiting agents
US11395820B2 (en) 2016-03-16 2022-07-26 H. Lee Moffitt Cancer Center And Research Institute, Inc. Small molecules against cereblon to enhance effector t cell function
US20170281784A1 (en) 2016-04-05 2017-10-05 Arvinas, Inc. Protein-protein interaction inducing technology
AU2017246452C1 (en) 2016-04-06 2021-06-03 The Regents Of The University Of Michigan MDM2 protein degraders
WO2017176958A1 (en) 2016-04-06 2017-10-12 The Regents Of The University Of Michigan Monofunctional intermediates for ligand-dependent target protein degradation
JP2019515932A (ja) * 2016-04-29 2019-06-13 アスター バイオテック リミテッド ライアビリティ カンパニー チロシンキナーゼｂｃｒ−ａｂｌ阻害剤としての新規複素環化合物
EP3454862B1 (en) 2016-05-10 2024-09-11 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
EP4491236A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Heterocyclic degronimers for target protein degradation
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
WO2017201069A1 (en) 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
EP3458101B1 (en) 2016-05-20 2020-12-30 H. Hoffnabb-La Roche Ag Protac antibody conjugates and methods of use
WO2017205762A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017205766A1 (en) 2016-05-27 2017-11-30 Pharmacyclics Llc Inhibitors of interleukin-1 receptor-associated kinase
WO2017207385A1 (de) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
GB201610147D0 (en) 2016-06-10 2016-07-27 Glaxosmithkline Ip Dev Ltd Novel compounds
JP7065840B2 (ja) 2016-06-27 2022-05-12 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４－ジアミノ－ピリミジン化合物ならびに該化合物の作製法および使用法
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
JP2019196309A (ja) 2016-09-15 2019-11-14 武田薬品工業株式会社 複素環化合物
US10925868B2 (en) 2016-11-10 2021-02-23 Dana-Farber Cancer Institute, Inc. Degradation of protein kinases by conjugation of protein kinase inhibitors with E3 ligase ligand and methods of use
CA3042731A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Inhibitors of interleukin-1 receptor-associated kinases and uses thereof
BR112019015484A2 (pt) 2017-01-31 2020-04-28 Arvinas Operations Inc ligantes de cereblon e compostos bifuncionais compreendendo os mesmos
TW202340194A (zh) 2017-02-16 2023-10-16 美商基利科學股份有限公司 吡咯并[1,2-b]嗒𠯤衍生物
PE20191817A1 (es) 2017-05-11 2019-12-27 Bristol Myers Squibb Co Tienopiridinas y benzotiofenos utiles como inhibidores de cinasa 4 asociada al receptor de interleucina 1 (irak4)
EP4717317A2 (en) 2017-06-20 2026-04-01 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
CN118108706A (zh) 2017-09-04 2024-05-31 C4医药公司 戊二酰亚胺
WO2019060693A1 (en) 2017-09-22 2019-03-28 Kymera Therapeutics, Inc. CRBN LIGANDS AND USES THEREOF
WO2019084030A1 (en) 2017-10-24 2019-05-02 Genentech, Inc. (4-HYDROXYPYRROLIDIN-2-YL) -HYDROXAMATE COMPOUNDS AND METHODS OF USE
EP3700901A1 (en) 2017-10-24 2020-09-02 Genentech, Inc. (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
IL315310A (en) * 2017-12-26 2024-10-01 Kymera Therapeutics Inc Irak degraders and uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
WO2019140387A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Crbn ligands and uses thereof
US11802132B2 (en) 2018-02-23 2023-10-31 Dana-Farber Cancer Institute, Inc. Small molecules for inducing selective protein degradation and uses thereof
US20220356185A1 (en) 2018-07-06 2022-11-10 Kymera Therapeutics, Inc. Mertk degraders and uses thereof
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160058872A1 (en) * 2014-04-14 2016-03-03 Arvinas, Inc. Imide-based modulators of proteolysis and associated methods of use
WO2017197051A1 (en) * 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Amine-linked c3-glutarimide degronimers for target protein degradation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE Pubchem U.S. National Library of Medicine; 20 October 2014 (2014-10-20), "5-(Aminomethyl)-5-(1H-indol-3-yl)piperidin-2- one", Database accession no. CID 83543479 *
DATABASE Pubchem U.S. National Library of Medicine; 22 October 2012 (2012-10-22), "5-(2-Oxoimidazolidin-1-yl)piperidin-2-one", Database accession no. CID 115370667 *
DATABASE Pubchem U.S. National Library of Medicine; 29 January 2016 (2016-01-29), "DCSIVLJIFSGTLY-UHFFFAOYSA-N", Database accession no. CID 63661460 *
LU ET AL.: "Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4", CHEMISTRY & BIOLOGY, vol. 22, 4 June 2015 (2015-06-04), pages 755 - 763, XP002774454, DOI: doi:10.1016/j.chembiol.2015.05.009 *

Cited By (154)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12441740B2 (en) 2017-06-20 2025-10-14 C4 Therapeutics, Inc. N/O-linked degrons and degronimers for protein degradation
US12180225B2 (en) 2017-06-20 2024-12-31 C4 Therapeutics, Inc. N/O-linked degrons and degronimers for protein degradation
US11459335B2 (en) 2017-06-20 2022-10-04 C4 Therapeutics, Inc. N/O-linked Degrons and Degronimers for protein degradation
US12540127B2 (en) 2017-09-22 2026-02-03 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11358948B2 (en) 2017-09-22 2022-06-14 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11524949B2 (en) 2017-11-16 2022-12-13 C4 Therapeutics, Inc. Degraders and Degrons for targeted protein degradation
US12570626B2 (en) 2017-11-16 2026-03-10 C4 Therapeutics, Inc. Degraders and degrons for targeted protein degradation
US11958837B2 (en) 2017-12-21 2024-04-16 Ribon Therapeutics, Inc. Quinazolinones as PARP14 inhibitors
US11723980B2 (en) 2017-12-26 2023-08-15 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11318205B1 (en) 2017-12-26 2022-05-03 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US10874743B2 (en) 2017-12-26 2020-12-29 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12168057B2 (en) 2017-12-26 2024-12-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11512080B2 (en) 2018-01-12 2022-11-29 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US11932635B2 (en) 2018-01-12 2024-03-19 Kymera Therapeutics, Inc. CRBN ligands and uses thereof
US12516068B2 (en) 2018-01-12 2026-01-06 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11753397B2 (en) 2018-03-26 2023-09-12 C4 Therapeutics, Inc. Cereblon binders for the degradation of ikaros
US11584748B2 (en) 2018-04-16 2023-02-21 C4 Therapeutics, Inc. Spirocyclic compounds
US12227504B2 (en) 2018-04-16 2025-02-18 C4 Therepeutics, Inc. Spirocyclic compounds
US12454520B2 (en) 2018-07-06 2025-10-28 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11897882B2 (en) 2018-07-06 2024-02-13 Kymera Therapeutics, Inc. Tricyclic crbn ligands and uses thereof
EP3817822A4 (en) * 2018-07-06 2022-07-27 Kymera Therapeutics, Inc. PROTEIN DEGRADANTS AND USES THEREOF
WO2020010227A1 (en) 2018-07-06 2020-01-09 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US11292792B2 (en) 2018-07-06 2022-04-05 Kymera Therapeutics, Inc. Tricyclic CRBN ligands and uses thereof
US12202829B2 (en) 2018-07-31 2025-01-21 Fimecs, Inc. Heterocyclic compound
US11639354B2 (en) 2018-07-31 2023-05-02 Fimecs, Inc. Heterocyclic compound
WO2020027225A1 (ja) 2018-07-31 2020-02-06 ファイメクス株式会社 複素環化合物
US11471455B2 (en) 2018-10-05 2022-10-18 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
US11944622B2 (en) 2018-10-05 2024-04-02 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
US11352350B2 (en) 2018-11-30 2022-06-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12258341B2 (en) 2018-11-30 2025-03-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11117889B1 (en) 2018-11-30 2021-09-14 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11807636B2 (en) 2018-11-30 2023-11-07 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
EP3886904A4 (en) * 2018-11-30 2022-07-13 Kymera Therapeutics, Inc. IRAQ DEGRADERS AND USES THEREOF
US12454521B2 (en) 2018-12-20 2025-10-28 C4 Therapeutics, Inc. Targeted protein degradation
JP7716554B2 (ja) 2019-04-05 2025-07-31 カイメラ セラピューティクス， インコーポレイテッド Ｓｔａｔ分解剤およびそれらの使用
CN113939300A (zh) * 2019-04-05 2022-01-14 凯麦拉医疗公司 Stat降解剂和其用途
US12077555B2 (en) 2019-04-05 2024-09-03 Kymera Therapeutics, Inc. STAT degraders and uses thereof
JP2022527114A (ja) * 2019-04-05 2022-05-30 カイメラ セラピューティクス， インコーポレイテッド 分解剤およびそれらの使用
US11746120B2 (en) 2019-04-05 2023-09-05 Kymera Therapeutics, Inc. Stat degraders and uses thereof
WO2020206424A1 (en) * 2019-04-05 2020-10-08 Kymera Therapeutics, Inc. Stat degraders and uses thereof
JP2025011088A (ja) * 2019-04-05 2025-01-23 カイメラ セラピューティクス， インコーポレイテッド Ｓｔａｔ分解剤およびそれらの使用
TWI875749B (zh) * 2019-04-05 2025-03-11 美商凱麥拉醫療公司 Stat降解劑及其用途
US11485750B1 (en) 2019-04-05 2022-11-01 Kymera Therapeutics, Inc. STAT degraders and uses thereof
EP3953332A1 (en) 2019-04-12 2022-02-16 C4 Therapeutics, Inc. Tricyclic degraders of ikaros and aiolos
WO2020215844A1 (zh) * 2019-04-25 2020-10-29 中国科学院化学研究所 用于筛选lrpprc调控剂的产品及鉴定lrpprc调控剂的方法
JP2020183905A (ja) * 2019-05-08 2020-11-12 国立大学法人高知大学 認知症治療薬のスクリーニング方法
JP7289510B2 (ja) 2019-05-08 2023-06-12 国立大学法人高知大学 認知症治療薬のスクリーニング方法
WO2020236901A1 (en) * 2019-05-20 2020-11-26 University Of Pittsburgh-Of The Commonwealth System Of Higher Education A novel therapy for erythropoietic protoporphyria (epp) and x-linked protoporphyria (xlp)
CN114096250B (zh) * 2019-05-20 2025-01-14 匹兹堡大学联邦高等教育系统 红细胞生成性原卟啉症(epp)和x连锁原卟啉症(xlp)的疗法
CN114096250A (zh) * 2019-05-20 2022-02-25 匹兹堡大学联邦高等教育系统 红细胞生成性原卟啉症(epp)和x连锁原卟啉症(xlp)的新疗法
US12528808B2 (en) 2019-05-20 2026-01-20 University Of Pittsburgh Of The Commonwealth System Of Higher Education Therapy for erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP)
US12521438B2 (en) 2019-06-10 2026-01-13 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US12496348B2 (en) 2019-06-18 2025-12-16 Dana-Farber Cancer Institute, Inc. Small molecule target bromo/acetyl proteins and uses thereof
AU2020295399B2 (en) * 2019-06-18 2025-10-16 Dana-Farber Cancer Institute, Inc. Small molecule target bromo/acetyl proteins and uses thereof
US12545659B2 (en) 2019-06-28 2026-02-10 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
JP2025113407A (ja) * 2019-06-28 2025-08-01 カイメラ セラピューティクス， インコーポレイテッド Ｉｒａｋ分解剤およびその使用
US12558427B2 (en) 2019-07-17 2026-02-24 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
US12559486B2 (en) 2019-07-17 2026-02-24 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
US12564578B2 (en) 2019-08-28 2026-03-03 University Of Kentucky Research Foundation Collagen P4H1 inhibitor and its use
WO2021041942A1 (en) * 2019-08-28 2021-03-04 University Of Kentucky Research Foundation Collagen p4h1 inhibitor and its use
CN110596403A (zh) * 2019-09-17 2019-12-20 中山大学附属第一医院 用于卵巢癌诊断的特异性蛋白标记物及制备方法
CN110596403B (zh) * 2019-09-17 2022-12-16 中山大学附属第一医院 用于卵巢癌诊断的特异性蛋白标记物及制备方法
US12310975B2 (en) 2019-10-17 2025-05-27 Arvinas Operations, Inc. Modulators of BCL6 proteolysis and associated methods of use
CN110749733A (zh) * 2019-12-06 2020-02-04 四川大学华西医院 Tgif2ly自身抗体检测试剂在制备肺癌筛查试剂盒中的用途
US12551564B2 (en) 2019-12-10 2026-02-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
JP2023507172A (ja) * 2019-12-17 2023-02-21 オリオニス バイオサイエンシズ，インコーポレイテッド タンパク質分解の調節
US11591332B2 (en) 2019-12-17 2023-02-28 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12546776B2 (en) 2019-12-17 2026-02-10 Orionis Biosciences, Inc. Modulation of protein degradation
US11707457B2 (en) 2019-12-17 2023-07-25 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US11779578B2 (en) 2019-12-17 2023-10-10 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12539295B2 (en) 2019-12-17 2026-02-03 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
US12371442B2 (en) 2019-12-20 2025-07-29 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of EGFR
WO2021127561A1 (en) 2019-12-20 2021-06-24 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
JP2023508914A (ja) * 2019-12-20 2023-03-06 カリコ ライフ サイエンシーズ エルエルシー プロテインチロシンホスファターゼ分解剤及びその使用方法
JP7828893B2 (ja) 2019-12-20 2026-03-12 カリコ ライフ サイエンシーズ エルエルシー プロテインチロシンホスファターゼ分解剤及びその使用方法
WO2021127586A1 (en) * 2019-12-20 2021-06-24 Calico Life Sciences Llc Protein tyrosine phosphatase degraders and methods of use thereof
EP4681715A2 (en) 2019-12-20 2026-01-21 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of egfr
US12486290B2 (en) 2019-12-20 2025-12-02 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of EGFR
US11673902B2 (en) 2019-12-20 2023-06-13 C4 Therapeutics, Inc. Isoindolinone and indazole compounds for the degradation of EGFR
US11679109B2 (en) 2019-12-23 2023-06-20 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
WO2021162493A1 (ko) * 2020-02-14 2021-08-19 보로노이 주식회사 단백질 키나아제 분해 유도 화합물 및 이의 용도
CN111214664A (zh) * 2020-02-24 2020-06-02 大连医科大学 USP2和HSP90抑制剂联合使用抑制ErbB2阳性乳腺癌生长的应用
US12049464B2 (en) 2020-03-05 2024-07-30 C4 Therapeutics, Inc. Compounds for targeted degradation of BRD9
US12157735B2 (en) 2020-03-05 2024-12-03 C4 Therapeutics, Inc. Compounds for targeted degradation of BRD9
US11691972B2 (en) 2020-03-05 2023-07-04 C4 Therapeutics, Inc. Compounds for targeted degradation of BRD9
EP3878847A1 (en) * 2020-03-13 2021-09-15 Centre Régional de Lutte contre le Cancer - Centre François Baclesse Bcl-2 family proteins modulating compounds for cancer treatment
WO2021180966A1 (en) * 2020-03-13 2021-09-16 Centre Regional De Lutte Contre Le Cancer Francois Baclesse Bcl-2 family proteins modulating compounds for cancer treatment
JP2023516790A (ja) * 2020-03-13 2023-04-20 サントル レジオナル ドゥ ルッテ コントル ル キャンサー フランソワ バクレシー 癌処置のためのｂｃｌ－２ファミリタンパク質調節化合物
CN115715286B (zh) * 2020-03-13 2024-12-13 弗朗索瓦巴克莱斯对抗癌症中心地区 用于癌症治疗的bcl-2家族蛋白调节化合物
CN115715286A (zh) * 2020-03-13 2023-02-24 弗朗索瓦巴克莱斯对抗癌症中心地区 用于癌症治疗的bcl-2家族蛋白调节化合物
CN115380026B (zh) * 2020-03-17 2023-11-07 南京明德新药研发有限公司 蛋白降解调节剂与其使用方法
CN115380026A (zh) * 2020-03-17 2022-11-22 南京明德新药研发有限公司 蛋白降解调节剂与其使用方法
JP2023517393A (ja) * 2020-03-17 2023-04-25 メッドシャイン ディスカバリー インコーポレイテッド タンパク質分解調整剤およびその使用方法
JP2023518422A (ja) * 2020-03-17 2023-05-01 カイメラ セラピューティクス， インコーポレイテッド Ｓｔａｔ分解剤およびそれらの使用
WO2021188696A1 (en) * 2020-03-17 2021-09-23 Kymera Therapeutics, Inc. Stat degraders and uses thereof
US11932624B2 (en) 2020-03-19 2024-03-19 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
US12528785B2 (en) 2020-03-19 2026-01-20 Kymera Therapeutics, Inc. MDM2 degraders and uses thereof
WO2021236885A1 (en) * 2020-05-21 2021-11-25 Dana-Farber Cancer Institute, Inc. Piperidine-2,6-diones as small molecule degraders of helios and methods of use
US11685750B2 (en) 2020-06-03 2023-06-27 Kymera Therapeutics, Inc. Crystalline forms of IRAK degraders
US12559492B2 (en) 2020-06-19 2026-02-24 C4 Therapeutics, Inc. BRAF degraders
KR102654220B1 (ko) 2020-07-07 2024-04-04 한국식품연구원 Cmip 억제제를 포함하는 지방간 질환의 예방 또는 치료용 약학적 조성물
KR20220006012A (ko) * 2020-07-07 2022-01-14 한국식품연구원 Cmip 억제제를 포함하는 지방간 질환의 예방 또는 치료용 약학적 조성물
WO2022012623A1 (en) * 2020-07-16 2022-01-20 Beigene, Ltd. Degradation of (egfr) by conjugation of egfr inhibitors with e3 ligase ligand and methods of use
JP2022025029A (ja) * 2020-07-17 2022-02-09 国立医薬品食品衛生研究所長 新規化合物及び医薬組成物
JP7692128B2 (ja) 2020-07-17 2025-06-13 国立医薬品食品衛生研究所長 新規化合物及び医薬組成物
JP2023545730A (ja) * 2020-10-07 2023-10-31 カイメラ セラピューティクス， インコーポレイテッド Ｓｔａｔ分解剤およびそれらの使用
WO2022077010A1 (en) * 2020-10-07 2022-04-14 Kymera Therapeutic, Inc. Stat degraders and uses thereof
WO2022109426A1 (en) * 2020-11-20 2022-05-27 Foghorn Therapeutics Inc. Compounds and uses thereof
US12606568B2 (en) 2020-12-09 2026-04-21 Kymera Therapeutics, Inc. SMARCA degraders and uses thereof
US12150995B2 (en) 2020-12-30 2024-11-26 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CN112899351A (zh) * 2021-02-03 2021-06-04 东华大学 一种双重荧光定量pcr检测pdx模型小鼠细胞浸润状态试剂盒
CN112899351B (zh) * 2021-02-03 2022-08-26 东华大学 一种双重荧光定量pcr检测pdx模型小鼠细胞浸润状态试剂盒
US12497402B2 (en) 2021-02-15 2025-12-16 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
US12171768B2 (en) 2021-02-15 2024-12-24 Kymera Therapeutics, Inc. IRAK4 degraders and uses thereof
WO2022216675A1 (en) * 2021-04-06 2022-10-13 Believe In A Cure, Inc. [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)- amino]-acetic acid for use in increasing foxg1 expression
US11986532B2 (en) 2021-04-16 2024-05-21 Arvinas Operations, Inc. Modulators of BCL6 proteolysis and associated methods of use
US12097261B2 (en) 2021-05-07 2024-09-24 Kymera Therapeutics, Inc. CDK2 degraders and uses thereof
CN113186273A (zh) * 2021-05-13 2021-07-30 中国人民解放军总医院第一医学中心 一种用于预测P2Y12受体拮抗剂抗血小板疗效的circRNA检测试剂盒及其应用
CN113186273B (zh) * 2021-05-13 2023-02-21 中国人民解放军总医院第一医学中心 一种用于预测P2Y12受体拮抗剂抗血小板疗效的circRNA检测试剂盒及其应用
US12486253B2 (en) 2021-06-08 2025-12-02 C4 Therapeutics, Inc. Therapeutics for the degradation of mutant BRAF
WO2022271727A1 (en) * 2021-06-21 2022-12-29 Calico Life Sciences Llc Degrader compounds and uses thereof
WO2023283130A1 (en) 2021-07-04 2023-01-12 Newave Pharmaceutical Inc. Isoquinoline derivatives as mutant egfr modulators and uses thereof
CN113817818A (zh) * 2021-10-22 2021-12-21 常州市第二人民医院 用于诊断过敏性气道炎症的工具
CN113817833A (zh) * 2021-10-26 2021-12-21 常州国药医学检验实验室有限公司 一种基于荧光定量pcr技术的检测宫颈细胞基因甲基化的试剂盒与应用
US12187744B2 (en) 2021-10-29 2025-01-07 Kymera Therapeutics, Inc. IRAK4 degraders and synthesis thereof
EP4444290A4 (en) * 2021-12-11 2025-11-26 Kymera Therapeutics Inc STAT3 DEGRADING AGENTS AND THEIR USES
WO2023107706A1 (en) * 2021-12-11 2023-06-15 Kymera Therapeutics, Inc. Stat3 degraders and uses thereof
KR102676912B1 (ko) 2021-12-14 2024-06-24 (주)프레이저테라퓨틱스 폴리유비퀴틴화에 의한 표적 단백질 또는 폴리펩티드의 분해용 신규 화합물
KR20230091051A (ko) * 2021-12-14 2023-06-22 (주)프레이저테라퓨틱스 폴리유비퀴틴화에 의한 표적 단백질 또는 폴리펩티드의 분해용 신규 화합물
US12091411B2 (en) 2022-01-31 2024-09-17 Kymera Therapeutics, Inc. IRAK degraders and uses thereof
CN114656509A (zh) * 2022-04-08 2022-06-24 国科温州研究院(温州生物材料与工程研究所) 一种氮杂环卡宾-金钯合金纳米粒子及其制备方法和应用
CN114656509B (zh) * 2022-04-08 2024-05-24 国科温州研究院(温州生物材料与工程研究所) 一种氮杂环卡宾-金钯合金纳米粒子及其制备方法和应用
WO2023225647A3 (en) * 2022-05-19 2023-12-28 University Of Puerto Rico Novel targets against ovarian cancer
WO2023232133A1 (zh) 2022-06-02 2023-12-07 西藏海思科制药有限公司 一种抑制或降解Bcl6的化合物及其在医药中的应用
US12421220B2 (en) 2022-06-06 2025-09-23 C4 Therapeutics, Inc. Bicyclic-substituted glutarimide cereblon binders
WO2023250058A1 (en) * 2022-06-22 2023-12-28 Kymera Therapeutics, Inc. Stat degraders and uses thereof
WO2024006781A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and use thereof
WO2024006776A1 (en) 2022-06-27 2024-01-04 Relay Therapeutics, Inc. Estrogen receptor alpha degraders and medical use thereof
WO2024075696A1 (ja) 2022-10-03 2024-04-11 公立大学法人横浜市立大学 二環性構造を有するイミダゾピリジン誘導体
CN115639306A (zh) * 2022-12-26 2023-01-24 四川大学华西医院 一种快速检测临床样本中抗癫痫药物浓度的方法
WO2024157953A1 (ja) 2023-01-24 2024-08-02 第一三共株式会社 置換ベンゼン化合物
EP4656635A1 (en) 2023-01-24 2025-12-03 Daiichi Sankyo Company, Limited Substituted benzene compound
CN116813608A (zh) * 2023-06-08 2023-09-29 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用
WO2025006783A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras
WO2025006753A2 (en) 2023-06-30 2025-01-02 Merck Patent Gmbh Heterobifunctional compounds for the degradation of kras protein
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
US12606533B2 (en) 2023-09-29 2026-04-21 Daiichi Sankyo Company, Limited 3-phenylpropylamine derivative
US20250144225A1 (en) * 2023-10-03 2025-05-08 PAQ Therapeutics Inc. KRAS Proteolysis Targeting Chimeras
US12599672B2 (en) * 2023-10-03 2026-04-14 PAQ Therapeutics Inc. KRAS proteolysis targeting chimeras
WO2025194014A1 (en) 2024-03-15 2025-09-18 Dem Biopharma, Inc. Hetero aryl modulators of apmap and uses thereof
US12565492B2 (en) 2024-08-09 2026-03-03 Triana Biomedicines, Inc. Anaplastic Lymphoma Kinase (ALK) degraders and uses thereof
CN120794955A (zh) * 2025-07-07 2025-10-17 四川伊诺唯新生物医药有限公司 一种irak4靶向蛋白降解剂关键中间体的制备方法

Also Published As

Publication number Publication date
EP3684365A1 (en) 2020-07-29
IL295603B1 (en) 2023-11-01
US20210238193A1 (en) 2021-08-05
US11623932B2 (en) 2023-04-11
IL322809A (en) 2025-10-01
JP2023175972A (ja) 2023-12-12
US20230115184A1 (en) 2023-04-13
EP4624467A2 (en) 2025-10-01
JP7366031B2 (ja) 2023-10-20
IL273432B (en) 2022-09-01
EP3684365A4 (en) 2021-09-08
CA3283159A1 (en) 2026-03-02
JP2025170324A (ja) 2025-11-18
IL295603B2 (en) 2024-03-01
AU2018338314A1 (en) 2020-04-09
AU2025201796A9 (en) 2025-04-17
US20260085075A1 (en) 2026-03-26
IL307995A (en) 2023-12-01
MX2022013526A (es) 2022-11-16
MX2023015185A (es) 2024-01-23
IL295603A (en) 2022-10-01
IL273432A (en) 2020-05-31
MX2020003190A (es) 2020-11-11
JP7818560B2 (ja) 2026-02-20
AU2018338314B2 (en) 2024-12-12
EP4624467A3 (en) 2026-03-11
AU2025201796A1 (en) 2025-04-03
CA3076613A1 (en) 2019-03-28
JP2020534375A (ja) 2020-11-26

Similar Documents

Publication Publication Date Title
US12006329B2 (en) Protein degraders and uses thereof
US12540127B2 (en) CRBN ligands and uses thereof
JP7818560B2 (ja) タンパク質分解剤およびそれらの使用
US11932635B2 (en) CRBN ligands and uses thereof
US11897882B2 (en) Tricyclic crbn ligands and uses thereof
US12454520B2 (en) Protein degraders and uses thereof
US20230093080A1 (en) Protein degraders and uses thereof
WO2021011631A1 (en) Fused-glutarimide crbn ligands and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18857581

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3076613

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2020538753

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018338314

Country of ref document: AU

Date of ref document: 20180921

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018857581

Country of ref document: EP

Effective date: 20200422

WWD Wipo information: divisional of initial pct application

Ref document number: 322809

Country of ref document: IL